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SUMMARY
1. In a pathological investigation of 53 cases of sudden death (age
range 3^ to 87 years), plasma cholesterol concentrations measured at 
autopsy were correlated negatively with age. There was a high incidence 
of thrombotic occlusion of the coronary arteries in cases under 60 years 
of age. In men of all ages, but not in women, cholesterol concentrations 
were significantly greater in cases with coronary arterial occlusion than 
in cases without.
2. In a clinical investigation, the serum concentrations of
cholesterol and triglyceride observed in the majority of aged men were 
within the normal range for younger people. The mean concentrations of 
both lipids, however, were elevated in aged men with JLHD compared with 
aged controls. In aged women with I Hi) concentrations of triglyceride, 
but not cholesterol, were elevated.
3. Preparative ultracentrifugation of serum lipoproteins showed that
HDL-cholesterol concentrations were greater in aged women than in aged 
men. HDL-cholesterol was significantly lower in aged men and women with 
TTTD than in aged controls. The majority of patients whose myocardial 
ischaemia was associated with supraventricular dysrhythmias did not 
have abnormalities of lipid metabolism.
4. Blood ascorbic acid concentrations in aged patients were low.
In men, WBC-ascorbie acid concentrations were significantly correlated 
with levels of HDL-cholesterol. Six weeks treatment with daily gram 
doses of ascorbic acid resulted in significant increases of mean HDL- 
cholesterol in the men, and in those women with LED.
5. The participation of ascorbic acid in lipid metabolism was not 
observed to be by any direct effect on LCAT activity.
6. Rheological studies showed that the elevated blood viscosity 
found in aged patients with IHD was associated with the haematocrit, 
but not with plasma fibrinogen concentration. Viscosity was not
elevated in patients with dysrhythmia-ischaemia. Treatment with ascorbic 
acid reduced fibrinogen concentration in nine patients whose initial 
levels had been elevated.
7* By integrating the pathological, clinical, metabolic, and 
rheological findings these studies have sought to show that 3HD in old 
age is not simply a consequence of ageing. Some metabolic abnormalities 
associated with IHD in aged patients responded to treatment with ascorbic 
acid and, in susceptible people, earlier long-term nutritional measures 
may aid in protecting against IHD in old age.
UNITS
Traditional units have heen used throughout. For conversion to
SI units the factors are as follows:
triglyceride, 1 mg/dl = 0.0113 mmol/l
cholesterol, 1 mg/dl = 0.0259 mmol/l
glucose, 1 mg/dl = 0.0555 mmol/l
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CHAPTER 1
INTRODUCTION
Ischaemic heart disease (nm) is the major cause of death in the 
Western world. During the past 50 years in England and Wales there 
has been a sharp increase in mortality from IHD; it now accounts for 
one third of the total deaths. Two thirds of the deaths from I Hi) 
occur in people aged over 65 years. Before considering the nature of 
IHD, however, it is' worth reflecting that the pumping action of the 
healthy heart is dependent on the contractile properties of the myo­
cardium, and also on the integrity of the specialised conducting tissue
which initiates and propagates the heart beat.
Normal Physiology of the Heart and Blood Vessels
The cardiovascular system can be considered to work as two pumps;
the right and left sides of the heart and the distensible pulmonary 
and systemic vessels, which offer resistance to the flow of blood through 
them. The arterial walls contain elastic fibres, collagen, smooth 
muscle, and nerve fibres, and the proportion of elastic tissue to muscle 
gradually decreases towards the periphery. The elastic arteries close 
to the heart act as reservoirs of blood, and dilate during ventricular 
contraction. When the ventricles relax in diastole, the arterial walls 
rebound, forcing blood to the periphery and maintaining a continuous 
flow (Figure l).
The atrio-ventricular valves, controlled by the papillary muscles, 
close a split second before ventricular systole. During this period, 
blood returning to the heart is retained in the distensible central 
veins and atria. When ventricular diastole supervenes, atrial . .systole 
completes the ventricular filling phase. The cardiac muscle fibres 
branch and anastomose with adjacent fibres to form a network and are 
capable of producing strong and rapid contractions without fatigue. 
Although the myocardium resembles skeletal muscle in chemical compo­
sition and metabolic processes (Keele and Neil,1965)> the most
Figure 1. Diagram illustrating elastic recoil of large 
arteries6near the heart in maintaining a 
continuous flow of blood 
(from Clegg and Clegg,1963)
important difference is that cardiac muscle cannot incur an oxygen 
debt. The myocardium receives its own blood supply via the coronary 
arteries and the effect of cutting off coronary blood flow is, 
therefore, grave. Coronary flow is affected partly by the mean 
systemic blood pressure but depends mainly upon the mean aortic 
pressure and the direct influence of metabolites on the coronary 
vessels themselves. An increased resistance in the aorta, producing 
a greater left ventricular work output, is associated with an increase 
in coronary flow linearly related to the oxygen usage of the ventricle 
(Clegg and Clegg,1963).
The initiation and propagation of the impulse for contraction in 
the heart takes place in the specialised conducting tissue (illustrated 
in Figure 2).
The concept most widely held today is that the conduction system 
is myogenic. However, there is a close association between nerves 
and conduction fibres throughout the heart (Davies, 1971) and a neuro­
genic theory of conduction has been proposed (Glomset and Cross,1952). 
The role of nerves may be to control the myogenic conduction system 
(Hoffman,1967) by regulating the heart rate.
The cardiac impulse normally originates in the sino-atrial 
(S-A) node, which is composed of an interwoven- mass of small muscle 
fibres intimately dispersed with fine collagen and elastic tissue.
The impulse is transmitted across the atria to the atrio-ventricular 
(A-V) node. The muscular arrangement of the atria excludes any simple 
radial spread of the impulse, and the presence of large atrial fibres 
resembling the Purkinje muscle fibres of the ventricle has been noted 
(Truex,196l; James,1963),
The A-V node, composed of small muscle fibres, fat, and fine 
connective tissue, very slowly conveys the impulse for contraction to
Figure 2. Normal conduction of cardiac impulse by 
specialised tissue 
(from Davies,1971)
S-A = sino-atrial node
A-V = atrio-ventricular node
HBB/IiBB = right/left bundle branches
the main bundle of His. This may serve to postpone ventricular 
contractions until atrial systole has been completed (Keele and Neil,
1965)* The bundle of His, composed of parallel muscle fibres, passes 
through the collagenous central body of the heart to the ventricles. 
Strands of fibres leave the left side to form the fan-shaped left 
bundle branch. Further small branches form a subendocardial network 
throughout the left ventricle (Esmond et al,1963). The right bundle 
branch is a direct continuation of the main bundle, and remains as a 
single, discrete muscle branch.
Normal Ageing Changes in the Heart and Conducting Tissue
A loss of elasticity in the vascular system is chiefly responsibl 
for a reduction in cardiac output with age. Ageing changes in the 
atria are accompanied by an increase in interstitial elastic tissue, 
collagen and fat, and a reduction in muscle tissue (Pomerance, 1976). 
Physiologically, the contractile properties of the myocardium are 
reported to decrease with age (Kohn and Rollerson,1959)« An increase 
in fibrosis in the heart valves causes them to become more rigid 
(McMillan and Lev,1964), and this, together with loss of elasticity 
and widening of the aorta, places the aged heart at a mechanical work 
disadvantage which may impair function (Roberts,1972).
In the specialised cardiac conducting tissue, a significant 
increase in adipose and fibrous tissue in the S-A node has been noted 
(Davies and Pomerance,1972) in patients over 75 years at death. This 
may be associated with changes in atrial rhythm and an increasing 
incidence of dysrhythmias, such as atrial fibrillation, with advancing 
age (Taran and Szilagyi,1958). Atrial fibrillation impairs the atrial 
augmentation required for adequate ventricular filling, resulting in a 
reduced cardiac output. In the ventricles, the major ageing change in 
morphology occurs in the collagen of the upper interventricular septum
where fibrous tissue increases, the collagen becomes amorphous and 
may break down into irregular calcified masses. Some degree of this 
change is universal by 60 years of age, and does lead to loss of 
conduction fibres even in patients with normal ECG. However, the 
same process has been described in cases of complete heart block 
(Lenegre,1964; Lev,1964) where there is far greater destruction of 
the conduction system than is found in normal hearts.
Ischaemic Heart Disease
The fundamental defect in IHD is an inadequate oxygen delivery 
to the myocardium as a result of impaired blood flow. IHD is generally 
associated with advanced coronary atherosclerosis or thrombotic 
occlusion, reducing or cutting off the blood flow to the myocardium. 
This results, in areas of ischaemia and,when severe, myocardial 
infarction. A common presenting feature is the chest pain of angina 
pectoris. The word 11 angina” (derived from the Greek ”to choke”) was 
first used by William Heberden in his lecture to the Royal College of 
Physicians in 1768. It was the only word commonly applied to 1 HI) in 
clinical practice for many years although Heberden himself did not 
recognise that the pain arose from the heart (Livesley,1975)* It 
was Caleb Parry in his book "Syncope Anginosa” (1799) who proposed 
that the pain of angina pectoris arose when the heart was provided 
with less blood than required. His colleague, Dr.Jenner, had observed 
gross calcification of the coronary arteries during a post-mortem 
examination of a patient with angina. Parry states: "that so far as 
the most accurate observation has hitherto gone, the tendency to this 
disorder arises from mal-organisation in the heart itself; which 
mal-organisation seems to be chiefly induration of the coronary 
arteries”. Not until the beginning of the 20th century, however, 
was it generally accepted that angina was a syndrome due to 
myocardial ischaemia.
Angina pectoris in patients with coronary arterial disease 
usually develops during physical exertion or emotional stress. A 
few patients, however, with normal coronary arteries may experience 
angina on exertion. Chest pain may also he associated with defects 
in the conduction system producing cardiac dysfdiythm; some patients 
experience "angina” at rest during episodes of spontaneous brady­
cardia, which results in inadequate coronary blood flow (bradycardiac 
angina). Paroxysmal tachyarrythmias.such as supraventricular tachy­
cardia can provoke "angina" by increasing myocardial oxygen demands, 
and decreasing the duration of diastole, resulting in impaired coronary 
perfusion. Defects of cardiac rhythm are particularly common in aged 
patients. However, the reduced physical activity of many old people 
may protect the myocardium from stress, and angina pectoris is a 
less frequent presenting feature of IHD in old age.
A major obstacle to an understanding of IHD lies in the profusion 
of terms and diagnostic classifications used by research workers. 
Although the term "ischaemic heart disease" is reasonably accepted as 
being synonymous with "coronary heart disease", "coronary arterial 
disease","cardiovascular disease" and other such terms, it could also 
logically cover the clinical situation of angina pectoris due to aortic 
valve disease or severe anaemia, or myocardial ischaemia resulting from 
dysrhythmias. Moreover, the diagnosis may be made clinically or at 
necropsy. Criteria for the clinical diagnosis of ischaemic heart 
disease have been classified by the World Health Organisation (1957» 
1959,1962) and are discussed in more detail in Chapter 3. The 
condition "IHD" will be considered here as being due to coronary 
atherosclerosis.
Pathology
Atherosclerosis is a pathological condition which can only be
diagnosed accurately post-mortem. Invasive techniques such as 
coronary arteriography are used only when necessary to confirm a 
clinical diagnosis. Pathologically, atherosclerosis (atheroma) is 
first seen as slightly raised, yellow, fatty streaks or spots (W.H.O. 
1958) that are thickenings of the arterial intima (stage i). A firm, 
fibrous plaque develops between the intima and the media (stage II). 
Large plaques can project sufficiently far into the arterial lumen 
to obstruct blood flow. When the;plaques contain much lipid material 
they soften (stage III) and finally, the surface of the plaque may 
break down to form an atheromatous ulcer (stage IV). Chemically, the 
atherosclerotic lesion may contain 8 times the concentration of lipid 
found in a comparable portion of healthy arterial intima (Adams,1959) 
the predominant lipid being cholesterol (Bottcher,1964; Smith,1965). 
Complete occlusion of the damaged artery may be effected by the 
formation of a thrombus, the mechanism of which differs from clot 
formation (Schwartz and Mitchell,1962). However, coronary athero­
sclerosis is commonly present in adult life with no clinical symptoms 
of cardiac disability (Short,1977)* A necropsy study on American 
soldiers killed in action in Korea (Enos et al,1955) at an average 
age of 22 years, showed a high incidence of coronary atheroma with 
complete coronary occlusion in 9 of the 300 apparently fit subjects.
Although various theories have been proposed regarding the 
pathogenesis of coronary atherosclerosis, no single hypothesis 
provides an entirely satisfactory answer. Indeed, it is becoming 
more obvious that coronary atherosclerosis has a multifactorial 
aetiology and that there may be no identical pathway in any two 
individuals.
Epidemiology of IHD and "risk" factors
Clues to aetiological or "risk" factors have been provided by
TABLE 1 Mortality from IHD (WHO, 197751978). Rates per 100,000 
population by age
Age Group
45-54 55-64 65-74 75+
Country Year
Scotland 1976 209 610 1361 3222
Finland 1974 221 560 1256 2807
Australia 1975 182 511 1268 3099
U.S.A. 1975 178 502 1196 3799
England & Wales 1976 161 456 1106 2756
Denmark 1976 126 397 1069 3730
Israel 1975 111 424 1239 3451
Netherlands 1976 112 317 845 2129
W.Germany 1975 87 271 758 2119
E.Germany 1976 60 177 573 1392
Greece 1975 47 162 353 867
Chile 1975 42 146 437 1427
Japan 1976 19 64 217 727
epidemiological studies. Mortality rates from IHD in thirteen" 
countries are shown in Table 1. Although the mortality rate in Japan 
was reported to be low, the incidence of IHD in Japanese immigrants 
in California was ten times greater than that of compatriots in 
Japan (Keys et al,1958). Thus various environmental, as well as 
inherited, factors have been identified which are associated with IHD.
Physical exercise may protect against the incidence and severity 
of the disease. Indeed, sedentary occupation has been shown to be a 
risk factor (Morris et al,1953> Morris and Crawford,1958; Brunner 
et al,1974). Cigarette smoking has been related to both mortality 
from, and incidence of, ischaemic heart disease (Buechley et al,1958; 
Spain and Nathan,196l).
The importance of genetic factors has been reviewed (Epstein,
1964). Associated diseases which increase the risk of developing 
TFTD include hypertension (Dawber et al,1957; Kannel et al,196l), and 
endocrine disorders which affect serum lipids, such as diabetes 
mellitus and myxoedema. Endocrine factors also account for the greater 
incidence of 1 HI) in men than in women until the menopause, after which 
the incidence in women increases,
a) Hyperlipidaemia
For many years attention has been focussed upon cholesterol, the 
major lipid component of atheromatous plaques, and the association 
between hypercholesterolaemia and IHD is well documented in epi­
demiological studies (Kannel et al,197l). However, hypertriglycerid- 
aemia has also been demonstrated as a risk factor by univariate and 
multivariate analysis (Carlson and Bottiger,1972; Pelkonen et al,1977). 
Patients with arteriographically proven coronary heart disease have a 
high incidence of lipid abnormalities (Falsetti et al,1968; Heinle 
et al,1969; Barboriak et al,1974). Hyperlipidaemia was shown to be
more common among survivors of myocardial infarction than among 
controls (Patterson and Slack,1972).
b) Diet
The dietary intakes of total fat (Keys,1953)> sucrose (Yudkin,
1966)j and animal protein (Yerushalmy and Hilleboe,1957) have been 
correlated with the incidence of IHD. However, in a recent review, 
Kritchevsky (1978) has shown that interaction among these dietary 
components can influence serum lipid levels and experimental athero­
sclerosis. Modification of dietary fats in the treatment of ischaemic 
heart disease has been attempted in men who had survived a myocardial 
infarction (Medical Research Council, 1965). Although the men given a 
low fat diet for six years had lower plasma cholesterol levels than a 
control group, the relapse rate was not significantly different. The 
mortality from coronary heart disease was reduced, however, in men in 
Finland given a cholesterol-lowering diet for 12 years (Miettenen et 
al,1972). Moreover, the dietary substitution of polyunsaturated fat 
for saturated (animal) fat not only reduced serum cholesterol levels, 
but also reduced the tendency to thrombus formation via an effect on 
blood platelets (0!Brien et al,1976a,1976b). A fatty meal eaten a 
few hours before withdrawal of blood has been shown to accelerate 
coagulation (Fullerton et al,1953) and inhibit fibrinolytic activity 
(Greig and Runde,1957).
An association between IHD and any one of these risk factors is 
not necessarily causal, although their control may aid in prevention 
of the disease. If each factor is of value in predicting IHD, the 
Framingham study (Dawber et al,1962) has shown that where more than 
one such identifiable factor was present, the risk of developing IHD 
was increased geometrically. This interaction of factors has been 
expressed mathematically (Walton,1975) and is illustrated in Figure 3*
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Pathogenesis of atherosclerosis
Any consideration of atherogenesis must account for the cause of 
sclerosis and the source of the lipid which accumulates. Stehbens 
(1974) has postulated that the mechanism initiating atherosclerosis 
is haemodynamic stress upon sections of the vessel wall at sites where 
blood flow is disturbed such as vessel branches and orifices. This 
may account for the focal location of the lesions. In such areas of 
very high shear, the arterial endothelium can be dislodged (Fry,1969). 
Endothelial injury may also be caused by micro-organisms and bacterial 
endotoxins5 antigen-antibody complexes; products formed from 
platelets or white cells; and possibly toxic environmental substances 
such as carbon monoxide (Mustard,1977). Animal experiments without 
dietary modification have shown that repeated injury to vessel walls 
produces fibrous plaques and atheromatous lesions rich in cholesterol 
(Moore,1973> Friedman et al,1975)« Apart from its role in initiating 
damage to the endothelium, blood flow can influence the site, growth 
and dissolution of arterial thrombi (Mustard,1975).
The thrombogenic theory of atherosclerosis was first proposed 
by von Rokitansky in the last century. The lesions arise when thrombi 
are deposited on the intimal surface of the arterial wall, and are 
later incorporated into the wall. Evidence to support this theory 
was later presented by Duguid (1948,1960), and it is possible that 
the layered appearance of the atherosclerotic lesions may result 
from repeated episodes of mural thrombosis in which persistent thrombi 
are organised into the vessel wall. More recent work has emphasised 
the role of platelets in the formation of thrombi, and by implication, 
in the development of atherosclerosis. Most thrombi which form on the 
damaged arterial endothelia consist initially of a mass of aggregated 
platelets (Mustard,1975) which adhere to the exposed collagen of the
subendothelium. In addition, the growth of the platelet thrombus 
is promoted by adenosine diphosphate (ADP) which is released from 
platelets in contact with collagen (Holmsen,1975). ADP can promote 
surface changes in the platelets which flow past the site of injury, 
causing them to adhere to one another and to those platelets already 
adherent to the vessel wall (Mustard and Packham,1970). Abnormalities 
in platelet function have been identified in certain disease conditions: 
platelet survival time is shortened in acute conditions such as myo­
cardial infarction, stroke and following surgery, and in chronic 
conditions such as atherosclerosis, hypertension, and vasculitis 
(Genton and Steele,1975). Platelet survival time may be related to 
the removal of platelets from the circulation after aggregation. The 
thrombogenic theory of atherogenesis does not convincingly account for 
the presence of lipids in the plaques. However, there is evidence for 
a link between lipid metabolism and platelet function. It has recently 
been shown that shortened platelet survival time and endothelial 
injury can result from the induction of hypercholesterolaemia (Ross 
and Harker,1976). This may be an important consideration in the 
contribution of elevated serum cholesterol levels to the development 
of atherosclerosis.
Virchow, in 1862, first suggested that the cholesterol content of 
atheromatous lesions arose from the "insudation" of plasma into the 
arterial wall, and Anitschkow, in 1933? produced arterial lesions 
experimentally by cholesterol feeding in animals. The lipids in 
atheromatous lesions resemble, qualitatively, the lipids in plasma, 
and although cholesterol synthesis can occur in the arterial wall, 
this source makes a negligible contribution to the cholesterol 
deposited in the lesions. Studies in rabbits have shown that atheroma­
tous cholesterol is derived from plasma (Newman and Zilversmith,1962; 
Zilversmith.,1968). In thirteen patients with atherosclerosis,
Jagannathan and colleagues (1974) demonstrated a slow but definite 
exchange of isotopic cholesterol between plasma and atherosclerotic 
arteries. This work suggested that atheromatous cholesterol is 
mobilisable, and thus a potential regression of atheromatous lesions 
in man. Indeed, severe malnutrition in man produces at least partial 
resorption of the lipids from atheroma (Adams,1973)• The "insudative" 
theory has been updated by Walton (1975)» whose evidence shows that 
in areas of increased vascular permeability entry of plasma proteins 
such as fibrinogen and the lower density lipoproteins is facilitated. 
Thus a key to the role of plasma lipids in atherogenesis lies in the 
nature of the polar lipoproteins in which cholesterol and triglyceride 
are transported.
Lipid Transport in Lipoproteins
As early as 1949 lipid circulation as hydrophilic lipoprotein 
particles was described by Gofman, and during the last decade much 
new information has been gathered regarding the composition and 
metabolism of the lipoproteins. The lipid transport system is 
traditionally separated into several lipoprotein classes defined by 
investigation of their physical, chemical and immunological properties. 
Various lipoprotein nomenclatures have been derived from the methods 
used in investigation; the terminology most usually employed for the 
lipoproteins of greatest clinical importance is based on their 
sedimentation characteristics: very low density lipoproteins (VLDL), 
low density lipoproteins (IjDL) and high density lipoproteins (HDL).
This terminology can be equated with designations based upon electro­
phoretic mobility, i.e. VLDL with pre-(3, LDL with (3, and HDL with cc 
lipoproteins. The properties and composition of each class of lipo­
protein are summarised in Figure 4.
Composition of Lipoproteins
The lipoproteins are almost certainly bound non-covalently.
. Triglyceride Phospholipid 
! □ □ □ □ □ □ □ (
Cholesterol
/. Chylomicron
Electrophoretic Origin 
mobility
Density 0o96
VLDL
Pre-p
LDL
P
HDL
a
G.96-1.006 1.019-1.063 1.05-1«21
Figure 4 Composition and some properties of lipoproteins
The chylomicrons, VLDL and LDL particles contain less than 30°/o 
protein and are thought to he micellar. Electron micrographs of 
these particles show them to he spherical (Saltpeter and Zilversmit, 
1968). A chemical model for micellar lipoproteins is that of a 
sphere with a protein surface whose polar (hydrophilic) side is 
exposed to the surrounding aqueous medium, and whose inner surface 
interacts with a 1:1 phospholipid-free cholesterol complex (Winkelman 
and Wybenga,1974). Interior to this are hydrophobic triglycerides and 
cholesterol esters. The HDL particles, which contain more than 30^ 
protein, are ’’pseudomolecular”. The lipid-protein subunits are 
associated in a definite quaternary structure.
The lipoproteins show a continuous tendency towards decreasing 
size, with an increase in particle density and protein content. As 
size is reduced, the triglyceride content decreases while the ratios 
of phospholipid and cholesterol increase. For clinical purposes it 
is sufficient to recall that LDL and HDL contain cholesterol as their 
major lipid, while triglyceride is the main lipid component of VLDL 
and chylomicrons.
The classification of lipoproteins into four main types is an 
approximation, since each class is heterogeneous. Efficient methods 
of separation can identify further lipoprotein subclasses. Five 
separate LDLs were described in the serum of a hypercholesterolaemic 
patient (Hammond and Fisher,1971). The protein per mole of lipoprotein 
remained constant and only the lipid content varied, in specific 
increments, between the five discrete LDLs. The HDL fraction has been 
subdivided into at least three density subfractions by analytical 
ultracentrifugation (Anderson,1978). Indeed, during recent years 
it has been shown that all plasma lipoproteins are metabolically 
related, and exist in a dynamic state of interconversion.
Lipoprotein Metabolism
The chylomicrons are synthesised in the intestine in response 
to dietary fat, and represent the transport of exogenous triglyceride. 
VLDL are synthesised in the liver in response to excess dietary 
carbohydrate or to mobilisation of fatty acids from adipose tissue, 
and are the main form of transport of endogenous triglyceride. The 
degradation of these triglyceride-rich lipoproteins and the uptake of 
their lipid constituents by tissues is dependent on enzymic activities 
residing at the luminal surface of the capillary endothelium. Intra­
venous heparin injection releases these lipid hydrolysing activities 
which are not normally present in plasma (Brown et al,1976). It has 
been suggested (Augustin et al,1976) that this post-heparin lipolytic 
activity consists of at least two lipases, the first being identical 
to the lipoprotein lipase (LPL) of adipose tissue and muscle, and the 
second being one of hepatic origin: hepatic triglyceride lipase.
The quantity of LPL released appears to be related to the level of 
circulating triglyceride in normal subjects. After lipolysis, the 
"remnant’1 VLDL particles contain only about 20fo  of the triglycerides 
present in the original VLDL (Eisenberg, 1976). It appears that, in 
man, the "delipidated" VLDL particle is converted, via intermediate 
particles (VLDL-IMP), to LDL (Eisenberg et al,1973)« In rats,however, 
VLDL-IMP is directly cleared from the bloodstream and catabolised in 
the liver, which explains the low level of LDL in rats.
The protein moiety of VLDL is composed of at least three apoprotein 
families: A, B and C. Apoprotein B (apo B) in VLDL is a major pre­
cursor in plasma of apo B in LDL, which contains only B apoprotein.
Apo B is regarded as a structural subunit of VLDL and LDL particles. 
Studies in humans (Bilheimer et al,1972; Havel et al,1973) and in rats 
(Eaergeman et al,1975) have shown that apoprotein C (apo C) units,
found in both VLDL and HDL, represent one common pool of apoprotein.
The transfer of apo C between VLDL and HDL can occur by an exchange 
phenomenon (Eisenberg et al,1972) or by transfer from VLDL to HDL 
during lipolysis, and from HDL to VLDL (and chylomicrons) during the 
synthesis and secretion of the latter (Eisenberg et al,1973). The C 
apoproteins have an important role in lipid transport in that, together 
with phospholipid, they behave as a cofactor in activating extrahepatic 
lipoprotein lipase (La Rosa et al,1970). The in vitro hydrolysis of 
non-lipoprotein triglyceride by LPL is enhanced up to 20-fold in the 
presence of apo C and phospholipid.
The globular A group of apoprotein residual in HDL reportedly 
activates the enzyme lecithin-cholesterol acyl transferase (LCAT) 
which is synthesised by the liver (Glomset and Norum,1973) and 
circulates in the plasma in association with HDL. LCAT catalyses 
the formation of cholesterol esters within the HDL particle by transfer 
of fatty acids from the phospholipid lecithin to free (unesterified) 
cholesterol (Levy et al,1976). This reaction may be of great importance 
in the control of lipoprotein metabolism during the catabolism of 
VLDL, when excess free cholesterol released from VLDL may be cleared 
from the circulation. However, the mode of clearance of esterified 
cholesterol, as well as other lipids bound to HDL, is not known.
Glomset (1968) hypothesised that transport of cholesterol from 
peripheral tissues to the liver,for catabolism,may be a function of 
HDL. A model of lipoprotein metabolism is illustrated in Figure 5. 
Lipoprotein Interrelations - clinical findings and effects of diet 
An inverse relationship has been noted between LDL and HDL 
concentrations in men and women in the United States (Nichols, 1967) 
and in men in Finland (Nikkila,1953)> and confirmed by Miller and 
Miller (1975). Inverse correlations between HDL-cholesterol and
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Figure 5 Hypothetic diagram illustrating lipoprotein 
metabolism
VLDL-triglyceride levels have been described (Carlson,1973> Gordon 
et al,1977> Anderson,1978) and an inverse correlation between HDL- 
cholesterol and VLDL-cholesterol levels was reported (Rossner et al, 
1978), Such findings confirm the close metabolic interrelation 
between lipoprotein species. Indeed, an inverse correlation between 
plasma triglyceride and HDL-cholesterol bolds for both normal and 
hyperlipidaemic subjects (Schaeffer et al,1978) and when hypertri- 
glyceridaemic subjects are given lipid-lowering diets, their HDL- 
cbolesterol levels usually rise. Carbohydrate feeding stimulates 
endogenous triglyceride production, and in subjects on diets high in 
carbohydrate (more than 7 gm/kgm daily) HDL levels are decreased 
(Levy et al,1976) owing to enhanced catabolism of the HDL apoproteins 
A-I and A-II, which also occurs in bypertriglyceridaemia.
Relation of Lipoproteins to Atherosclerosis and Clinical IBP
The hyperlipidaemias have been classified in terms of lipoprotein 
disorders by Fredrickson (1968) and revised by the World Health 
Organisation (Beaumont et al,1970) and possible defects of lipoprotein 
metabolism producing each disorder have been suggested by Carlson 
(1976), Whether the disorder is familial or secondary to endocrine 
or other disease states (Chait,1973) or to diet, raised levels of 
VLDL (pre-p lipoprotein) or of LDL ((3-lipoprotein) are associated 
with increased risk for coronary atherosclerosis and hence, for I HP.
The influence of individual lipoprotein levels on the severity 
of coronary atherosclerosis (determined by angiography and given a 
score) has been investigated (Jenkins et al,1978). It was shown that 
levels of LDL-cholesterol, total cholesterol, and a combination of 
LDL-cholesterol with VLDL-triglyceride, were each positive correlated 
with the coronary atherosclerosis score. Conversely, a strong negative 
correlation was observed between HDL-cholesterol levels and the coronary
atherosclerosis score. Much clinical evidence is now available to 
support Glomset*s (1968) hypothesis of the role of HDL in cholesterol 
transport. Cholesterol tissue pool values in 8 hypercholesterolaemic 
patients were shown to be unrelated to the mean plasma concentrations 
of total cholesterol, total triglyceride, VLDL or LDL (Miller et al,
1973) but negatively correlated with plasma HDL-cholesterol, Species 
resistant to atherosclerosis, such as dogs and rats, have low levels 
of plasma LDL and relatively high HDL concentrations (Zilversmit,1975> 
Eisenberg,1976), Berg and colleagues (1976a), using an immunological 
system to determine HDL, showed that male survivors of myocardial 
infarction in Northern Sweden had significantly lower concentrations 
of HDL than heal thy, middle-aged men. They also demonstrated lower 
HDL levels in male patients with angiographically proven coronary 
arterial disease than in those with no angiographic changes (Berg 
et al,1976b), A recent prospective case control study (Miller et al,
1977) of over 6,000 men living in Tromso, Norway, showed future 
clinical coronary heart disease to be inversely related to HDL-cholesterol 
concentration and directly related to LDL- and VLDL-cholesterol,
These relationships were independent of one another and the predictive 
contribution of HDL-cholesterol to future clinical coronary arterial 
disease was three times greater than that of lower density lipoproteins. 
Similar findings have been reported for men and women in the Framingham 
prospective study (Gordon et al,1977). In young patients with 
ischaemic cerebrovascular disease (Rossner et al,1978) total serum 
triglyceride, cholesterol, and LDL-cholesterol levels were similar 
to those found in controls, but HDL-cholesterol was significantly lower 
in the patients. The mortality from IHD is three times greater in men 
in Edinburgh than in Stockholm men (Logan et al,1978) and investigations 
showed that although total cholesterol and LDL-cholesterol levels were
similar in the two populations, HDL-cholesterol levels were lower in 
the Edinburgh men. Total triglycerides, and triglycerides in each 
lipoprotein fraction^were greater in men in Edinburgh,
Lipids, Thrombosis, and Myocardial Infarction
Lipid metabolism seems to be linked in some ways to platelet 
function, and by implication, to thrombus formation. In patients with 
raised levels of LDL, in whom early-onset coronary arterial disease 
is a risk (Slack, 1969), platelet reactivity to ADP is enhanced 
(Bolton et al,1967; Carvalho et al,1974) increasing their Mstickiness11 
(Mustard and Packham, 1970) and furthermore, the platelet content of 
phospholipid (Nordoy and Rodset,197l) and of free cholesterol 
(Meittenen,197^) is increased. When human platelets are incubated 
in a cholesterol-rich medium, their aggregability is greatly increased 
(Shattil et al,1975). In cholesterol-fed monkeys, endothelial injury 
is induced, and platelet survival time is shortened (Ross and Harker,
1976) since platelets adhere to areas of endothelial damage.
Platelet survival time is related to removal of platelets from 
the circulation after aggregation, Following experimental arterial 
injury, the growth of smooth muscle-cells, characteristic of athero­
sclerosis, appears to be initiated by platelets, and LDL and insulin 
appear to have a supportive role (Ross et al,1974). Dietary substi­
tution of polyunsaturated fat for saturated fat in man (0*Brien et 
al,1976a,1976b) reduced not only serum lipid levels, but also platelet 
sensitivity to activating agents, A decrease in thrombotic tendency 
may therefore contribute to the protection by polyunsaturated fat 
diets (Meittenen et al,1972) against THD.
Although abnormal platelet function has been reported in myocardial 
infarction (Hampton and Mitchell,1966; 0*Brien et al,1966) coronary 
thrombosis as a major cause of myocardial infarction has been disputed
(Roberts and Buja,1972; Haerem, 1975)• Sudden death associated with 
coronary arterial disease is not usually associated with evidence of 
thrombotic occlusion of the coronary arteries (Spain and Bradess,1970; 
Haerem,1975)* Coronary thrombosis can occur without myocardial 
infarction (Blumgart et al,194l) and myocardial infarction can occur 
without occlusive thrombus. However, in patients who survive a day 
or longer after initial symptoms, large thrombi are usually found 
(Friedman et al,1973> Chandler et al,1974). Since the contents of 
a thrombus are continuously breaking down and reforming (Mustard,
1977) there is no isotopic marker system presently available to 
establish whether the thrombus was formed before or after the clinical 
event. Mustard (1977) suggests that micro-emboli which form from 
mural thrombi in the myocardial circulation may be a cause of sudden 
death. Certainly, mural thrombi in the carotid artery can fragment, 
and obstruct the retinal and cerebral circulation to produce transient 
blindness and cerebral ischaemia (Gunning et al,1964; Torvik and 
Jorgensen,1966) and Haerem (1972) found an increased incidence of 
platelet aggregates in the microcirculation of patients with coronary 
arterial disease dying suddenly, compared with accidental death victims. 
He also found an increase in small mural thrombi in the coronary 
arteries of those dying suddenly from myocardial ischaemia (Haerem,
1974).
Effects of Blood Flow and Viscosity
Thrombosis is rare except in arteries with atherosclerotic 
narrowing (Baroldf, 1976; Mustard,1977)> illustrating the importance 
of blood flow in arterial thrombosis. Patterns of blood flow can 
determine the size of a thrombus which forms in arteries (Mustard,
1977) and when blood flow is disturbed, such as at a point of arterial 
branching, or at a stenosis, the extent of thrombus formation is
greater than in regions of undisturbed flow (Goldsmith,1972). Blood 
flow is influenced by the radius of the vessels, the pressure gradient 
and by blood viscosity. Although blood flow can depend on the work 
done by the heart, this work correlates with the viscosity of blood 
(Dintenfass,1975). Reduced blood flow certainly increases the 
incidence of venous thrombosis (Clark and Cotton,1968) and it has been 
suggested that an increase in blood viscosity alone is a prime cause 
of thrombosis (Leading article,1975) but there is no decisive evidence.
Blood viscosity is influenced by the haematocrit (packed cell 
volume), plasma protein and fibrinogen concentration, erythrocyte 
flexibility, and vessel bore. Cerebral blood flow was measured in 38 
patients with haematocrit values over 46°/o (Thomas et al,1977) and was 
found to be significantly lower than in patients with haematocrit 
below 4G /o , When the haematocrit in patients with high values was 
reduced by venesection, cerebral blood flow greatly increased. This 
improvement in flow coincided with a reduction in blood viscosity.
Blood viscosity, haematocrit, and plasma fibrinogen concentrations 
were all significantly higher in patients with angina than in normal 
controls (Nicolaides et al,1977). When the viscosity was corrected 
to a standard haematocrit of 45^, however, no significant difference 
in mean viscosity was found for patients and controls, suggesting that 
the raised haematocrit mainly influenced the higher viscosity in 
patients with angina.
An increased blood viscosity was associated with reduced calf 
blood flow in patients with intermittent claudication (Dormandy et al,
1973). a clinical symptom of peripheral vascular disease. In some of 
these patients increased viscosity seemed to be the determining cause 
of claudication. In patients with definite clinical HID as well as 
peripheral vascular disease, blood viscosity was significantly higher
than in those with peripheral vascular disease alone. The prevalence 
of hyperlipidaemias was greater in patients with claudication than in 
controls. The most common biochemical abnormality, however, was a 
raised plasma fibrinogen level, and fibrinogen was correlated positively 
with blood viscosity measured at high shear-rates. Stormer and 
colleagues (1974) also demonstrated higher plasma and blood viscosities 
in patients with peripheral vascular disease compared with controls and 
significantly greater fibrinogen concentrations in the patients. 
Cholesterol and triglyceride levels were significantly greater in 
patients with the disease, and cholesterol and viscosity values were 
positively correlated. Fibrinogen is believed to affect viscosity 
by increasing red cell aggregation (Rosenblum,1969) possibly by macro- 
molecular bridging (Chien et al,197l). It has been reported (Wardle 
et al,1973) that raised plasma fibrinogen levels in diabetic patients 
were associated with the onset of major cardiovascular complications 
within three years. Whole blood viscosity is also raised in diabetics 
at low shear rates (Barnes et al,1977) and may predispose to venous 
thrombosis.
Older patients were less able to maintain cerebral blood flow 
in the presence of a higher viscosity (Thomas et al,1977) and it is 
therefore likely that maintenance of blood flow peripherally,and in 
the coronary arteries when viscosity is increased, is further reduced 
with ageing. The maintenance of blood flow under conditions of 
increased viscosity would imply an increase in blood pressure and 
cardiac work load or a reduction in peripheral resistance by vaso­
dilation. These compensatory mechanisms become less efficient with 
age (Shock,1962).
HID in the Elderly
The vast bulk of the research in the aetiology and pathogenesis
of IHD has been concerned with young and middle-aged subjects. Scant 
attention has been paid to the problem in the elderly, yet two-thirds 
of the deaths registered in the United Kingdom as being due to TTTD 
occur in the over 65*s (Registrar General,1976). Furthermore, as a 
result of the elimination of many infectious diseases and of an 
improvement in medical care, more people are surviving to an advanced 
age, and the number of cases of IHD involving persons over 65 years 
is increasing.
That ageing itself is not a disease is illustrated by the well- 
known fact that some reach advanced old age with little obvious impair­
ment of physical or mental capacity. However, a number of structural 
and functional changes which occur at different stages in individual 
subjects can be accepted as senescent processes (Rockstein,1975) and 
for some, ageing is accompanied by a variety of disabling degenerative 
changes.
The age-associated loss of elasticity in the vascular system is 
chiefly responsible for resistance to blood flow, with an increase in 
blood pressure and reduction in cardiac output. The reduced blood 
flow can contribute to ischaemia of cerebral, cardiac and peripheral 
tissue and also to functional changes in organs such as the kidney, 
where it is reflected in a reduced glomerular filtration rate (Richey,
1975). Such loss of elasticity has been attributed to molecular 
changes in collagen (Bjorksten,1977; McClain,1977) whose tendency 
to form cross-linkages (and thus enhance rigidity) increases with 
age.
Although the degree of coronary atherosclerosis is said to 
increase with age (Pathy, 1976) and Masoro (1975) has suggested 
atherosclerosis to be an inevitable aspect of ageing in the United 
States, the studies of Pomerance (1976) have shown that many in their
nineties have coronary arteries almost free of atheroma. The ageing 
changes which occur in the specialised cardiac conducting tissue 
have been described (p.8) and may contribute to the rising incidence 
of dysrhythmias (such as atrial fibrillation) (Davies,1971) which can 
add their own contribution to myocardial ischaemia- in advancing age.
Physiologically, the contractile properties of the myocardium are 
reported to decrease with age (Kohn and Rollerson,1959) resulting in 
an increased cardiac pre-ejection period in aged subjects (Montoye et 
al,197l)« When exercise or emotional stress produce tachycardia, the 
aged myocardium reacts poorly, but providing there is sufficient rest 
between beats, it can support an adequate output by prolonging the 
duration of systole (Harris,1975).
Despite the diminished tolerance of the myocardium to stress, heart 
failure in the aged is usually precipitated by pathological conditions 
such as acute coronary arterial disease, hypertension, acute infections, 
complications of drug therapy, and valvar heart disease. A combination 
of abnormalities is a feature of cardiac pathology in the elderly 
(Pomerance,1976) and a cumulative effect is apparent in the majority of 
cases of cardiac failure. The most important single cardiac abnormality 
in the aged in functional terms is IHD. An ischaemic pathology was 
found in half of the geriatric patients dying in cardiac failure 
(Pomerance, 1965; Pomerance and Hodkinson,1976). The proportion is 
greater in cases of sudden death outside hospital. In 380 cases of 
sudden death over 65 years, 62P jo were due to coronary arterial disease 
(Pomerance, 1976). The cardiac lesions are usually relatively large 
areas of recent necrosis or fibrous scarring.
Clinically, cardiovascular diseases can present unique problems 
in the elderly and the significance to community health cannot be 
over-emphasised. The clinical features of IHD in this age group often
differ from the classical presentation in younger people.
Acute myocardial infarction frequently occurs without, or with 
minimal, pain and may he overlooked. Indeed, myocardial infarction 
may he discovered only at necropsy. The sudden onset of intense 
dyspnoea or nocturnal cough may denote an otherwise 11 silent” 
infarction. Evans and Sutton (1956) and Ebert (1965) considered that 
pain might be overshadowed by intense dyspnoea. Occasionally, acute 
confusion may be the only symptom of infarction (Pathy,1976) which 
can produce cerebral anoxia. The infarction may be unobserved if it 
exacerbates existing confusion, or if it is accompanied by cerebro­
vascular stroke. Strokes subsequent to myocardial infarction are 
sometimes due to cerebral emboli arising from the heart (Carter,1964) 
and 64°Jo of all arterial emboli from cardiac infarction were found to 
involve arteries of the brain (Wright et al,1954). However, the 
reduced cardiac output and marked hypotension following myocardial 
infarction can impair cerebral arterial perfusion, which may result 
in cerebral infarction (Rogers,1955) particularly if cerebrovascular 
disease is present.
In acute myocardial infarction, necrosis of atrial muscle is 
associated with the development of atrial fibrillation, and James 
(1968) has suggested that the rhythm disturbance is related to injury 
to the sino-atrial node. Occlusion of the artery to the sino-atrial 
node (derived from the atrial and coronary arteries) has been stressed 
as a factor in the pathogenesis of atrial fibrillation (Davies,1971)• 
Thus, hypoperfusion of this artery occurring during a transient 
dysrhythmia may precipitate a similar effect.
The early detection and treatment of rhythm disorders has been 
emphasised in the prevention of disturbed brain function in aged 
patients, since Livesley (1977) reported a high incidence of cardiac
dysrhythmia in elderly patients with hrain failure. Intellectual 
deterioration in old age can result from repeated episodes of 
reduced cardiac output, producing cerebral hypoperfusion and 
ischaemia.
The aged patient with heart disease may have complicating 
diseases unrelated to the cardiovascular system but which modify the 
severity of his condition. A study of morbid conditions at death in 
over 700 elderly men (Lake,1969) showed that 86^ died with a major 
infection, such as bronchopneumonia, superimposed on other lesions 
which themselves predispose to death. Old myocardial lesions were 
found in 27°/o and gross atheroma in 28^. Clinical surveys of disease 
incidence in the elderly are likely to underestimate or misdiagnose 
the diseases present (Howell,1966).
Despite the high mortality from IHD in the elderly, acute 
coronary disease is a relatively uncommon recognised cause of their 
admission to hospital (Thould,1965). The incidence of painless myo­
cardial infarction in Thould!s hospital study was 52°/o , suggesting 
that many elderly patients do not contact their doctors and may die 
without reaching hospital. Gross coronary atheroma was found in 69°J> 
of patients examined at post-mortem, and there was a significant 
incidence of atherosclerosis in the cerebral vessels and aorta.
Wright (i960) observed that lesions in older patients are distributed 
as a generalised atherosclerosis, whereas in younger patients the 
pathological changes which produce clinical symptoms are usually 
confined to the area of the heart.
Lipids and IMP in the Aged
Investigations of biochemical changes associated with IHD in the 
aged are limited. A study of 500 survivors of myocardial infarction 
(Goldstein et al,1973) showed that in survivors over 70 years old,
hyperlipidaemia was present in only a quarter of the women, and almost 
absent in the men, while the incidence of lipid abnormalities in those 
under 50 was high. However, even in the absence of hyperlipidaemia, ? 
controlled studies have shown cholesterol levels to be significantly 
higher in elderly men with IHD than in those without (Brown and 
Ritzmann,1967) and significantly correlated with IHD incidence in aged 
men and women (Yavrik et al,1974). No such relationships were found 
between lipid levels and I.HD in aged Ashkenazi Jews (Schadel et al,
197l) but the clinical criteria used in the diagnosis of IHD in this 
study were questionable. A prospective study in Stockholm (Carlson 
and Bottiger,1972) of risk factors for IHD showed no relationship 
between triglyceride or cholesterol levels and future events of IHD 
in men over 60 years. It appears that in men, serum levels of 
cholesterol and triglycerides begin to fall after the sixth decade 
(Wood et al,1972) while in women, lipid levels rise following the 
menopause, but may decline in advanced old age. Women tended to 
have higher serum cholesterol levels than men in each decade between 
60 and 90 years (Vavrik et al,1974) although the incidence of higher 
levels ^bove 250 mg/dl) declined with age in both sexes.
Very little information is available for lipoprotein levels in 
old age. To the extent that LDL-cholesterol and VLDL-triglyceride 
levels reflect levels of total cholesterol and fasting total tri­
glyceride levels, respectively, it is likely that these fractions are 
lower in old age. The evidence of Gordon and colleagues (l977) for 
subjects up to 80 years showed no age trend in HDL-cholesterol in men, 
but a slight reduction in LDL-cholesterol, while in women there was a 
small decrease in HDL-cholesterol between 50 and 80 years. A study of 
50 men and 50 women over 90 years of age in Amsterdam (Danner et al,
1978) showed that mean total cholesterol and fasting triglyceride levels
were very low, particularly in the men. HDL-cholesterol levels 
appeared to he in the normal range for younger populations (Carlson 
and Ericsson,1975). Obesity was infrequent, and clinical cardio­
vascular disease was found in only 28 subjects, although ECG abnormal­
ities (unspecified) were present in 8 7 °/o . Dietary analysis showed 
that proportions of the major nutrients and polyunsaturated fats were 
similar to those in the diets of the total Dutch population.
It is not known whether the lower lipid levels found in advanced 
age are due to metabolic or hormonal changes which represent a "normal 
ageing process, or whether the lipid patterns are characteristic of a 
genetically select group who have either survived hyperlipidaemia or 
who have never exhibited lipid abnormalities. A longitudinal follow- 
up of a large series of people surviving to advanced age is required. 
Since dietary modification has been shown to affect lipoprotein levels 
in young subjects, nutritional changes in old age could reasonably be 
expected to contribute to altered lipid metabolism. A reduced total
energy requirement reflects the age-associated decline in basal
(
metabolic rate and physical activity. As far as is known at present, 
requirements for the essential nutrients are not significantly changed 
in old people, but dietary habits do change together with social, 
economic and physical factors, and may lead to deficient intake of 
some essential nutrients and an imbalance of others.
Many elderly people consume a high proportion of calories as 
carbohydrate which, as has been mentioned,can enhance catabolism 
of HDL apoproteins (Levy et al,1976). The elderly may absorb iron 
less efficiently, and often appear deficient in ascorbic acid (Exton— 
Smith, 197l)* Iron absorption is enhanced by the simultaneous admini­
stration of ascorbic acid, which may be due to its reducing properties 
to a chelating effect or to an unknown mechanism (Hughes, 1974). Wide-
spread deficiency of this vitamin was found in elderly patients on 
admission to, and in, hospital (Griffiths et al,1967). There is now 
evidence to show that ascorbic, acid can modify lipid metabolism and 
atherogenesis.
Ascorbic Acid and Lipid Metabolism
Ascorbic acid acts as a redox couple in the conversion of proline 
to hydroxyproline in collagen synthesis. Its physiological functions 
include the promotion of wound healing and the maintenance of 
connective tissue, cartilage, bone and capillaries. As a cellular 
antioxidant it maintains membrane structure, and protects hyaluronic 
acid, a constituent of intercellular cement. Ascorbic acid is also a 
cofactor in the synthesis of catecholamines from dopamine (Levin,
196l) and protects epinephrine against oxidation (Kutsky,1973).
These functions may account for its role in maintaining vascular tone 
(Burns,196l) other than by maintenance of structural integrity.
Acute or clinical scurvy is probably rare (Turley,1967). A 
potentially more prevalent health risk is the subclinical state 
arising from chronic dietary ascorbic acid deficiency.
In his analysis of the nature of.atherosclerosis Aschoff (1924) 
postulated that the earliest morphological lesion is a disturbance of 
the intercellular ground substance of the arterial intima. Willis 
(1953) produced lesions in guinea pig arteries identical to those in 
human atherosclerosis by feeding an ascorbic acid deficient diet. 
Further work (Willis,1957) in scorbutic guinea pigs showed that early 
atherosclerotic lesions were more resistant to treatment. Deficiency 
states increase susceptibility to vascular stress (Burns,1961).
The role of ascorbic acid in cholesterol metabolism has been 
demonstrated in guinea pigs(Ginter and Nemec,1969). It was proposed 
that acute scurvy and chronic latent ascorbic acid deficiency have
different metabolic effects. Acute scurvy disturbs metabolism of the 
acetate pool, depressing glycogenesis and synthesis of fatty acids, 
and stimulating cholesterologenesis. Animals with chronic deficiency 
were shown to have an increase in total hepatic cholesterol content, 
but there was no disturbance in oxidation of acetate to carbon 
dioxide, nor a significantly altered incorporation of labelled acetate 
into hepatic cholesterol. Further work in hypovitaminotic animals 
(Ginter et al,197l) demonstrated an accumulation of cholesterol in 
other tissues, including the aorta wall, and raised serum cholesterol 
levels. It was shown that the rate of conversion of cholesterol to 
bile acids in these animals was significantly retarded and furthermore, 
that a significant direct correlation existed between the ascorbic 
acid concentration in the liver and the rate of cholesterol conversion 
to bile acids (Ginter,1973). A significant negative correlation 
existed between hepatic ascorbic acid concentration and both hepatic 
and serum concentrations of cholesterol. Ginter*s work suggests that, 
in the guinea pig, concentrations of cholesterol in serum and liver 
are controlled by the rate of its conversion to bile acids. The 
participation of ascorbic acid in bile acid synthesis may be in its 
regulation of the rate-limiting enzyme, cholesterol 7 cc-hydroxylase.
The concentration of cytochrome which is a cofactor in the 7
oc-hydroxylation of cholesterol, is reduced in scorbutic guinea pigs, 
and replenished after ascorbic acid therapy.
Results of studies in man have been variable. Cheraskin and 
Ringsdorf_ (1968) demonstrated a relationship between serum cholesterol 
concentrations and ascorbic acid intake. Spittle (l97l) examined the 
effects of oral administration of ascorbic acid on serum cholesterol 
in 58 healthy volunteers and 25 patients with atherosclerosis. In the 
control group under 25 years of age, serum cholesterol levels fell
after six weeks supplementation. Little change was observed, however, 
in the control group between 25 and 45 years. The atherosclerotic 
group showed a significant increase in cholesterol levels, and it was 
suggested that this increase was due to mobilisation of atheromatous 
cholesterol. Actual ascorbic acid levels in plasma and leucocytes 
were not estimated. Other workers (Anderson et al,1972; Sokoloff 
et al,1966) have been unable to demonstrate any effect of ascorbic 
acid therapy in normocholesterolaemic individuals. During therapy 
in hypercholesterolaemic subjects, Sokoloff and colleagues (1966) 
recorded marked reductions of cholesterol esters in some individuals 
after one year, with an overall trend towards normal values. Further­
more, ascorbic acid therapy in hypercholesterolaemic subjects with 
initially low blood ascorbic acid levels (Ginter et al,1970) produced 
a decrease in plasma cholesterol. However, no significant change 
was detected (Peterson et al,1975) in hypercholesterolaemic patients 
with normal initial blood ascorbic acid levels, after only eight 
weeks treatment.
Ascorbic acid supplements were shown to have a marked effect on 
plasma triglyceride levels in animals and in human subjects with 
lipid disorders (Sokoloff et al,1966). In these subjects, triglyceride 
levels were reduced by an average of 50-70^. This was associated 
with a striking increase in plasma lipoprotein lipase activity.
Plasma ascorbic acid levels were strongly correlated with HDL-cholesterol 
levels in aged men (Bates et al,1977) but not with total plasma 
cholesterol. Triglyceride values were not reported. These findings 
may be associated with an effect on lipoprotein lipase activity, or 
perhaps with an effect on LCAT. The evidence presented suggests that 
chronic dietary ascorbic acid deficiency may be a risk factor in the 
pathogenesis of atherosclerosis.
While enormous advances have been made in the various fields of 
research into IHD, our knowledge of the aetiology and pathogenesis 
of atherosclerotic lesions remains incomplete. The long and unresolved 
debate between proponents of the different theories of pathogenesis 
who have searched for a single cause has tended to obstruct progress. 
Furthermore, the dynamics and evolution of atherosclerotic plaques 
in man can only be reconstructed from static postmortem material.
Man!s long life-span, and the inability of the investigator to control 
all of the many variables associated with IHD, have led to the use of 
animal models for in vivo investigations whose relevance to human 
atherosclerosis requires cautious interpretation.
In man, the pathologist is able to relate arterial lesions to 
ischaemic lesions in the myocardium, but may have no history of clinical 
or biochemical abnormalities presenting during life. Often he is 
dealing with unselected cases of sudden death where the coroner 
requires a diagnosis.
For the clinician, the classical symptoms of IHD such as angina 
pectoris are easy to interpret, but the vague and often variable 
presentation of IHD in aged patients is not. The hospital clinician 
is dealing with a select population in whom diagnosis of IHD may be 
supported by electrocardiogram evidence and relevant biochemical 
information. When the clinical and electrocardiographic features 
are equivocal, however, his diagnosis may be confirmed only by use 
of invasive techniques or at autopsy.
Epidemiologists have related biochemical, physiological and 
environmental risk factors to both mortality from, and incidence 
of, IHD. Surprisingly little of such information is available for 
persons over 65 years, in whom two-thirds of the total deaths from 
IHD in the United Kingdom occur. The disabling effects of clinical
JHL) are particularly severe in the aged patient and the number of old 
people requiring care in institutions is increasing. I HI) is too 
readily dismissed as an inevitable consequence of ageing, and 
metabolic abnormalities which may relate to IHD in the aged have 
attracted little interest.
Since each field of research is limited and indeed may be investi­
gating different sections of the population, an understanding of the 
development of IHD in old age may only be brought about by a long­
term follow-up to autopsy of large numbers of people surviving to 
advanced age. In the absence of such a study, the present work was 
undertaken to investigate some metabolic factors which may be of 
importance to IHD in old age. In order to obtain as comprehensive 
a.picture as possible, the problem has been approached from four 
viewpoints: that of the pathologist; the clinician; the nutritionist; 
and the rheologist. The pathologistfs observations of coronary 
vessel status have been related to age and to cholesterol levels 
measured at autopsy. Fasting cholesterol and triglyceride levels in 
old men have been measured in relation to the clinician* s findings of 
IHD and of myocardial ischaemia associated with dysrhythmias. The 
effects of treatment with a nutritional factor, ascorbic acid, upon 
lipoprotein levels in aged men and women with IHD have been examined. 
Finally, some of the properties of blood influencing viscosity and 
flow have been explored in aged patients. It is hoped that this 
work will show that IHD in old age is affected not by normal ageing 
changes alone, but also by variables of which some, at least, might 
be controlled.
CHAPTER 2
THE PATHOLOGIST *S VIEW
Ischaemic heart disease is seen by the pathologist as lesions in 
the myocardium with necrosis of muscle tissue or replacement of 
necrotic areas with cellular or fibrous scar tissue. The only 
detectable change in the first 24 hours, however, may be recognised 
histologically as a marked variability of muscle fibre staining 
(Mitchell and Schwartz, 1963). From the second to the sixth day the 
affected muscle fibres become necrotic. At the end of this period the 
healing phase and the removal of necrotic fibres begins, during which 
the cellular pattern is characterised by lymphocyte infiltration and 
fibroblastic proliferation. Beyond the fourth month, the necrotic 
muscle has been removed and the lesion consists of dense collagen with 
a few lymphocytes and new blood vessels.
The lumen of the coronary arteries supplying the myocardium may 
be encroached upon by progressive stenosis (narrowing) which can vary 
in length and degree of intrusion. The tunica intima can thicken with 
advancing age in a proliferative repair process distinct from athero­
sclerosis (Adams,1973). Stenosis is otherwise produced by lipid 
accumulation within an atheromatous plaque, or by platelet-fibrin 
accretion upon an ulcerated plaque or area of endothelial damage.
Total occlusion of the lumen may occur by rupture of an atheromatous 
plaque or by acute thrombosis.
Schwartz and Mitchell (1962) found that the larger myocardial 
lesions were related to severe coronary stenosis and to coronary 
occlusion, and could justly be termed "myocardial infarction". Further 
work (Mitchell and Schwartz,1963) showed that single, recent large 
lesions were strongly associated with thrombotic occlusion of the 
coronary arteries, rather than with the severity of stenosis alone. 
Others (Baroldi et al,1978; Enos et al,1955) have emphasised that 
coronary stenosis, even when severe, is not synonymous with myocardial
ischaemia, and that the degree of ischaemia is not proportional to 
the size and number of stenoses. This suggests that at least one 
other factor, which is not anatomical, may be involved. Sudden death 
associated with I HI) is not always associated with evidence of occlusive 
coronary thrombosis (Roberts and Buja,1972; Haerem,1975). When 
present, however, occlusive thrombus is always located at the site of 
a severe, old stenosis (Baroldi et al,1974). These apparent contra­
dictions may be explained by the development of a collateral circulation. 
In the normal human heart, intramyocardial branches of the coronary 
arteries are connected with adjacent branches by an extensive anastomotic 
system. The vessels of this system enlarge in diameter and length in 
proportion to the degree and number of slowly developing stenoses 
(Baroldi et al,1978), compensating for the partial obstruction,although 
collateral blood supply in man may not be adequate for stressful 
situations (Gorlin,1978). It is possible that emboli from mural thrombi 
in this microcirculation are a cause of sudden death; indeed, a greater 
incidence of platelet aggregates was found in the microcirculation of 
those dying suddenly with coronary arterial disease than in those dying 
in accidents (Haerem,1972). However, since thrombi and emboli in the 
microcirculation can break up, it is difficult to demonstrate at 
autopsy in man that the emboli are involved in sudden cardiac death, 
in the same way that present marker systems cannot establish whether 
arterial thrombus was a cause or an effect of a clinical complication.
There is, at present, no biochemical or other measurable factor 
available to identify individuals at immediate risk for developing 
acute heart attacks except for the known risk of dysrhythmias. While 
prospective epidemiological surveys have indicated that hypercholesterol- 
aemia is one risk factor for the development of IHD, it has been 
reported (Oliver, 1978) that the majority of individuals with hyper-
cholesterolaemia have not suffered an acute heart attack ten years 
later* Nevertheless, a high incidence of lipid abnormalities has 
been found in those with angiographic evidence of coronary arterial 
disease (Falsetti et al,1968; Heinle et al,1969; Barboriak et al,
1974); and furthermore, cholesterol levels have been positively 
correlated with the extent of coronary arterial occlusion seen radio- 
graphically (Barboriak et al,197A; Jenkins et al,1978). The following 
investigation is a report of a pathologists findings in cases of 
sudden death where no previous medical history was available to 
indicate the cause of death. Plasma cholesterol levels in cases with 
thrombotic occlusion of the coronary arteries or with recent myocardial 
infarction were compared with levels found in cases without such 
evidence, in both young and aged men and women.
PLASMA. CHOLESTEROL LEVELS AND CORONARY VESSEL STATUS AT AUTOPSY 
Materials and Methods
Autopsies were performed in 53 cases of sudden death in 
Shropshire where there was no previous medical history and no indication 
of the cause of death.
Ten mis of lysed blood were collected by needle aspiration from 
the right atrium into sequestrene tubes at the earliest moment during 
the autopsy. Great care was taken to avoid contamination by tissue 
fluid. The plasma was separated and stored at 3°C before analysis 
for cholesterol in the Clinical Gerontology Unit, St.Francis Hospital, 
London. These analyses were performed without the autopsy findings 
being known.
The coronary arteries were examined throughout their length for 
stenosis and thrombosis. Stenosis was recorded if the lumen was 
reduced to 1 mm or less at any point, and thrombosis if recent or old 
clot occluded the lumen. The heart was opened, washed out and weighed
and the myocardium was examined for recent infarction or discrete 
areas of fibrosis.
Total plasma cholesterol was determined manually by the 
Liebermann-Burchard reaction (adapted from Abell et al,1952). Since 
the time between death and collection of blood varied, the stability 
of total cholesterol in whole blood, serum and plasma was demonstrated 
for over seven days at room temperature. These observations agree 
with previous reports (Grafnetter et al,1967; Troy and Purdy,1969). 
Although plasma samples from 103 cases were collected, 50 of these 
were considered unsuitable for estimation of cholesterol owing to 
haemolysis.
The cholesterol concentrations in cases with thrombotic occlusion 
and/or recent myocardial infarction were compared with levels in those 
cases without complete occlusion of the coronary arteries, using 
Student*s t test. The relation of cholesterol concentrations to age 
was determined.
Results
The age range for the cases was 34 to 87 years. Examination of 
the coronary vessels and left ventricular myocardium showed that 28 
of the 53 cases studied had evidence of occlusive thrombus in the 
coronary arteries, or of myocardial infarction. (Details are given 
in the Appendix). The incidence of thrombosis was greater in the 23 
cases under 60 years of age, i.e. 74$, compared with 37$ of cases 60 
years and over. Stenosis, without thrombosis, in the coronary arteries 
was recorded in 47$ of cases over 60 years of age. The variation of 
cholesterol levels with age is shown in Figure 6. The correlation 
coefficient was negative and highly significant (p <  0.001).
Cholesterol levels for all cases were significantly higher in 
those with thrombosis than in those without (p <  O.Ol) (Table 2).
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TABLE 2 Cholesterol Levels in Atrial Blood and Coronary Vessel 
Status at Autopsy
Cholesterol levels, mean +_ SE, m g /6 1
p
Thrombotic Non-thrombotic
. i
All cases 
(n = 53)
294 + 13 244 + 11 < 0.01
Female cases 
(n = 17)
246 + 25 255 ± 35 N.S.
Male cases 
(n = 36)
314 + 13 237 + 10 <0.001
Males <i 60 yrs 
(n = 18)
331 + 16 255 ± 19 < 0.001
Males >  60 yrs
(n = 18)
281 + 18 229 + 10 < 0.02
This relationship was highly significant when male cases were 
considered alone (p < O.OOl), while no difference between the means 
was observed for female cases alone. Furthermore, the relationship 
had greater significance in men under 60 years of age (p < O.OOl) than 
in men 60 years and over (p < 0.02).
Discussion
Cholesterol levels in vivo in a "normal” population have been 
shown to rise with age, at least in men, until the sixth decade 
(Fredrickson et al,1967; Reed et al,1972). After this age they 
fall (Wood et al,1972). The cholesterol levels found at autopsy in 
our select group of cases of sudden death were correlated negatively 
with age. Although Pomerance (1976) reported that 62^ of cases of 
sudden death over 65 years outside hospital were due to coronary 
arterial disease, acute thrombosis in aged individuals is an unusual 
cause of admission to hospital (Thould,1965), Indeed, the incidence 
of stenosis without thrombosis was 47^ in the present series of cases 
over 60 years of age, with occlusive thrombus or myocardial infarction 
evident in only 379^ j compared with three-quarters of the cases under 
60 years.
Radiographic studies have shown that cholesterol levels are 
correlated with the degree of narrowing of the coronary arteries 
(Jenkins et al,1978; Barboriak et al,1974). The present study shows 
that in men, mean cholesterol levels were greater in cases with 
occlusive thrombus than in cases without, the majority of the latter 
having stenotic narrowing. If it can be assumed that total cholesterol 
levels in plasma from atrial blood collected at autopsy reflect total 
plasma cholesterol levels at the time of the event of sudden death, 
these findings suggest an association between elevated cholesterol 
levels and a tendency to thrombus formation; and thus that thrombosis 
was more likely to have been a cause of death than a result. There is 
at present no evidence to link cholesterol levels in patients with 
clinical I HI) with levels found at post mortem following sudden death 
from I HI).
Although levels of cholesterol fell with advancing age at death, 
the mean levels in men aged 60 years and over remained significantly 
greater in those with occlusive thrombus than in those without, but 
the significance of the difference was weaker than that found in 
younger men.
CHAPTER 3
THE CLINICIAN’S VIEW
The World Health Organisation (1957) has defined TFTD as ’’the 
cardiac disability, acute or chronic, arising from the reduction or 
arrest of blood supply to the myocardium in association with disease 
in the coronary arterial system”. The clinical classification of 
J E D  (WHO,1962) is based upon its presenting features.
Other than sudden death, a common, and often the only, presenting 
feature of I HP is angina pectoris, which can vary from a sense of sub- 
sternal oppression to a dull, severe and constant gripping pain across 
the chest, and which may radiate to the shoulders, arms or jaws. 
Typically, the angina is induced by exertion, such as uphill walking, 
and is rapidly relieved by rest and by glyceryl trinitrate tablets.
In some patients, however, angina is also experienced at rest, and 
other than emotional stress, the precipitating factors are unknown. 
Bradycardiac angina (Parry’s syncope anginosa) is experienced by a few 
patients with JLHD during Stokes-Adams attacks. Anginal episodes 
usually have a short duration of between 2 and 15 minutes.
Acute myocardial infarction is usually distinguished clinically 
by severe 6hest pain of several hours duration. The pain is resistant 
to glyceryl trinitrate and independent of exertion. The condition is 
associated with shock, fever, acute left ventricular failure and 
characteristic electrocardiographic (ECG) changes (WHO,1959)* Old 
myocardial infarction may be documented in a clinical history of acute 
infarction; denoted by the presence of cardiac aneurysm and confirmed 
by the presence of a typical ”Q” wave on ECG (WHO,1959).
In the majority of patients who have I HD there are no abnormal 
physical signs. .LHP without pain may be asymptomatic, in which case 
the diagnosis can only be made in a hospital department using serial 
ECG information. The ECG changes recorded during and after exercise 
are of particular value in diagnosis (Livesley and Oram, 1973). In
other patients who have IlHi) without pain, chronic myocardial damage 
can produce effects which are non-specific for iHi), including chronic 
heart failure, atrial fibrillation and heart block. "Silent" or 
atypical myocardial infarction can occur without pain, particularly 
in aged patients, in whom the sudden onset of breathlessness or 
confusion may be the dominant clinical signs. Other symptoms can 
include shock or weakness, the sudden development of pulmonary oedema, 
or congestive cardiac failure.
The diagnosis of JUD in aged patients in the community is 
frequently masked since classical symptoms may be absent or ill-defined 
in character. The reduced need for physical exertion within the daily 
activities of later life protects the myocardium from stress, and 
increasing exertional dyspnoea may be dismissed by the patient as a sign 
of old age. Ultimately, overt heart failure may be accelerated acutely 
by the stress of an infection such as pneumonia.
Multiple, small myocardial infarcts are common in old age and 
often produce few, or no symptoms. The presenting clinical features 
in nearly 600 patients over 65 years with myocardial infarction con­
firmed by ECG have been recorded by Pathy (1976) and are shown in 
Table 3. These represent only admissions to hospital and therefore 
constitute a select group. Nevertheless, the diversity of clinical 
symptoms in these aged patients is striking.
Recovery from an acute myocardial infarction is often related to 
the site and extent of the lesion. If the specialised conducting 
tissue (Eigure 2) is affected by ischaemia, infarction, or age- 
associated changes, the patient’s condition may be complicated by the 
development of dysrhythmias. The incidence of atrial fibrillation rises 
with age, both in association with overt 1111) and as a lone abnormality 
(Taran and Szilagyi,1958). Ageing changes in the conduction system have
TABLE 3 Clinical Presentation of Myocardial Infarction and 
Acute Coronary Occlusion in 597 Patients Aged 65 
Years and Over
(From Pathy,1976)
Mode of Presentation Number of 
cases
°/o
Sudden dyspnoea or exacerbation 
of heart failure
119 19.9
Onset with chest pain 115 19.3
Acute confusion 69 11.6
Sudden death 42 7.0
Syncopal attacks 39 6.6
Strokes 38 6.4
Limb ischaemia 28 4.7
Giddiness or vertigo 27 4.5
Palpitation 26 4.4
Weakness 19 3.2
Renal failure 18 3.0
Recurrent vomiting 16 2.7
Pulmonary embolus 12 2.0
Uncontrolled diabetes 11 1.8
Restlessness 9 1.5
Cough 5 0.8
Sweating 4 0.7
been described (Lev,1954) which include an increase of fibrous and 
elastic tissue in the sino-atrial node with fatty replacement of 
nodal fibres. Others (Hudson,1965; Rossi,1969) found no ageing 
changes in the sino-atrial node of normal subjects. Heart block, 
often transient, may be associated with acute myocardial infarction, 
in which 5% of episodes are complicated by atrioventricular nodal 
block (Julian et al,1964; Meltzer and Kitchel1,1966). Chronic, 
acquired, complete atrioventricular block, however, is most commonly 
associated with bilateral bundle branch fibrosis of unknown aetiology 
(Davies,1971) and the clinical picture of syncopal attacks associated 
with a slow pulse was described by Adams (1827) and Stokes (1846).
The majority of patients with atrioventricular block followed up to 
autopsy had presented clinically with the bradycardia of Stokes- 
Adams attacks (Harris et al,1969).
In aged patients the few studies that relate clinical I Hi) to 
levels of serum cholesterol (Brown and Ritzmann,1967; Vavrik 
et al,1974) have not attempted to distinguish between THD considered 
to be associated with coronary arterial disease, and myocardial 
ischaemia associated with dysrhythmias. In some aged patients, a 
combination of these features may be present. The pathologistfs 
findings previously described showed that in older men dying suddenly, 
cholesterol levels in atrial blood were higher in those men with 
evidence of thrombotic occlusion of the coronary arteries than in 
those without. The following study relates the clinical diagnosis of 
LBD in aged men in hospital to serum levels of cholesterol and tri­
glycerides and to lipoprotein electrophoretic patterns. Levels of 
these lipids found in aged controls were compared with levels found 
in patients with dysrhythmia-ischaemia as well as those in patients 
with undoubted evidence of THD.
SERUM CHOLESTEROL AND TRIGLYCERIDE LEVELS IN AGED MEN WITH IHD
Patients and Methods
Forty-two men admitted to an acute hospital ward were selected 
for investigation in the absence of: anaemia; valvar heart disease; 
a known myocardial infarction within the previous three months; and 
known possible causes of secondary hyperlipidaemia (Chait,1973)
(Table 4). The patients were divided into three groups following 
routine clinical examination and ECG;
Group 1: 15 patients had no clinical or ECG evidence of IHD or
cardiac dysrhythm and acted as controls.
Group 2: 12 patients had clinical evidence of IHD
and this was confirmed by ECG (WHO,1959).
Group 3: 15 patients had ECG evidence of myocardial ischaemia
associated with supraventricular dysrhythmia.
TABLE 4 Some Causes of Secondary Hyperlipidaemia 
(Adapted from Chait,1973)
Condition Lipid Affected
Diabetes mellitus Triglyceride
Alcoholism Triglyceride
Obstructive liver disease Cholesterol
Chronic renal failure Triglyceride
Hypothyroidism Cholesterol and
triglyceride
Gout Triglyceride
Ten ml of venous blood were collected from each patient after 
a 14-hour overnight fast, and the serum was separated at the 
earliest opportunity.
Total serum cholesterol was determined manually by the 
Liebermann-Burchard reaction (Abell et al,1952).
Total serum triglycerides were estimated by the manual technique 
of Van Handel and Zilversmit (19-57)•
Lipoprotein electrophoresis was performed on agarose gel (Noble,
1968).
All determinations were made in duplicate. The lipoprotein 
profiles were assessed on a visual, qualitative basis (Fredrickson 
et al,1967; Beaumont et al,1970). The profiles obtained for pheno- 
typing in younger patients are illustrated in Figure 7. A typical 
profile found in aged control patients was used here as a basis for 
comparison, since the cholesterol and triglyceride levels found in 
these aged men were too low to satisfy the criteria required for 
phenotyping in younger patients (Winkleman and Wybenga,1974). Serum 
cholesterol and triglyceride levels obtained from the aged control 
group were compared with those from other groups using Student’s t- 
test.
Results
The ages of the 42 men ranged from 67 to 92 years (mean 79 
years). The age ranges and means within each group are shown in Table 
5. Of the fifteen patients in Group 3> seven had atrial fibrillation, 
five had cardiac conduction abnormalities including complete heart 
block, and three had supraventricular tachycardia.
TABLE 5 Serum Lipid Levels in Aged Men
Group 1 Group 2 Group 3
n = 15 n = 12 n = 15
Age range (mean),yrs 69-90(78) 67-92(79) 70-90(79)
Cholesterol ,mean + SE, 162 +_ 5 204 +  9 185 +. ®
mg/dl
Triglyceride,mean + SE, 73 i  5 115 + 13 79 ±  7
■> +
Figure 7
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Electrophoretic patterns 
hyperlipoproteinaemias
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lib
III
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V
of types I-V
The highest cholesterol level recorded in any group was only 
, 250 mg/dl, which is at the upper range of normal for younger men.
The mean serum cholesterol level (Table 5) for patients with TFT)
(Group 2) and the mean cholesterol level for patients with dysrhythmia- 
ischaemia (Group 3) were both significantly greater (p <" 0.001, 
p < 0.03, respectively) than the mean for aged controls.
Only 3 of the 42 men investigated had fasting triglyceride levels 
exceeding 150 mg/dl, which is commonly accepted as the upper limit of 
normal in younger patients. The highest level recorded here was 
215 mg/dl. Fifty-eight percent of the aged men had fasting triglyceride 
levels below 100 mg/dl. Nevertheless, the mean level for Group 2 
patients with IHD (Table 5) was significantly greater than the mean 
for the control group 1 (p <  0.01) or for the Group 3 patients (p<0.02). 
There was no correlation between levels of cholesterol and triglyceride 
in any of the 3 groups.
Although the lipid levels found in the aged men were low, it was 
possible to compare lipoprotein electrophoretic patterns with a typical 
"normal" profile found in the control group. The lipoprotein 
"abnormalities" observed were comparable with Frederickson*s classi­
fication types Ila, lib and IV (Figure 7)« Of the fifteen patients 
in the control group only one abnormal profile (type lib) was seen.
Of the twelve profiles for patients with IHD (Group 2) seven were 
classed as abnormal; three were type Ila, one type lib, and three 
type IV. Of the fifteen profiles for the dysrhythmia-ischaemia Group 
3, two were type Ila and one was type IV.
Discussion
In the 42 men investigated, all the serum levels of total 
cholesterol and the majority of those for triglycerides would be 
considered normal for a younger population (Fredrickson et al,1967>
Reed et al,1972). Cholesterol levels in aged individuals were low 
in other studies (Brown and Ritzmann,1967; Vavrik et al,1974) hut 
triglyceride levels were not reported. Indeed, Vavrik et al (1974) 
observed that, irrespective of sex, there was a negative correlation 
between the prevalence of cholesterol levels above 250 mg/dl and 
advancing age. The pathology results in Chapter 2 showed a strong 
negative correlation between cholesterol levels at autopsy and age 
at death. However, both Brown and Ritzmann (1967) and Vavrik et al 
(1974) found a significant relationship between serum cholesterol 
levels and clinical IHD in old people. The present work in aged men 
has shown that levels of both cholesterol and triglycerides were 
higher in men with clinical and ECG evidence of IHD than in aged 
controls. Significantly higher total cholesterol levels were also 
observed in patients whose myocardial ischaemia was associated with 
supraventricular dysthythmias than in controls, suggesting a multiple 
aetiology. However, triglyceride levels were not elevated in the 
dysrhythmic group and only 20Jo of patients with dysrhythmia had a 
comparatively abnormal lipoprotein profile compared with 58^ of 
patients with IHD and no rhythm disturbances.
In men aged over 60 years Carlson and Bottiger (1972) found no 
relationship between plasma cholesterol or triglyceride levels and 
the future development of IHD. The differences observed here in levels 
of these lipids between aged male controls and patients with JllD may 
simply reflect the later stages of an established disease process in 
survivors. The late onset of clinical IHD in aged patients may be 
associated with long-standing coronary arterial obstruction whose 
effects are aggravated by ageing changes in the contraction properties 
of the myocardium (Kohn and Rollerson,1959) and by reduced blood flow 
during dysrhythmias. Despite the low levels of lipids found in the
aged men, there was an association between the presence of THD and 
levels of cholesterol and triglycerides. The recent dietary 
history of each of the patients in hospital was assumed to be similar.
CHAPTER 4 
THE NUTRITIONIST'S VIEW
The nutritionist is broadly concerned with factors that relate 
IHD, biochemical abnormalities, and diet. Thus his interest may lie 
in the epidemiology, clinical biochemistry, treatment and prevention 
of the disease.
Epidemiology cannot provide final proof of a causal association 
between disease incidence and other characteristics of a population, 
particularly in IHD where a combination of factors increase or diminish 
risk. However, it can provide clues. The hyperlipidaemias were shown 
to be major risk factors for IHD, both between populations (Keys, 1970; 
Logan et al,1978) and within populations (Kannel et al,1971> Carlson 
and Bottiger,1972).
Increased plasma-lipid concentration is associated with a genetic 
tendency (Slack,1974), endocrine and other disorders (Chait,1973) and 
diet. The latter has repeatedly received attention in epidemiology 
since some consider IHD to be a disease of over-indulgence. Thus,any 
caloric source (lipid, carbohydrate or protein) which converts a 
marginal diet to an affluent one may be implicated as atherogenic. 
However, non-caloric sources including fibre, minerals, trace elements 
(Kritchevsky,1978), and vitamins,may also be involved.
Any dietary change which reduces serum lipid levels may be of 
importance both in the treatment and in the prevention of IHD. While 
endogenous hypertriglyceridaemia (raised VLDL) is readily treated by 
low carbohydrate feeding, cholesterol levels respond slowly to dietary 
changes. However, diets high in polyunsaturated fats can reduce serum • 
cholesterol levels in men (Dayton et al,1962; Christakis et al,1966), 
lower the further incidence of myocardial infarction in male survivors 
(Leren,1966) and reduce mortality from IHD (Meittenen et al,1972). 
Polyunsaturated fats may also reduce thrombus formation by an effect 
on platelet activation (O'Brien et al,1976). Plant pectin protects
laboratory animals against atherosclerosis (Erschoff,1963) and lowers 
plasma cholesterol in man (Keys et al,196l; Jenkins et al,1974; Kay 
and Truswel1,1977)> but wheat fibre has no effect.
Ascorbic acid status has been shown to modify serum and tissue 
cholesterol levels in animals (Ginter,1971»1973)> and serum lipid 
levels in some, but not all, human subjects (Sokoloff et al,1966;
Ginter et al,1970; Spittle,1971)• Moreover, atheromatous lesions 
identical to those in man have been produced in guinea pigs by a 
dietary deficiency of ascorbic acid (Willis,1953>1957).
The mechanisms by which these dietary factors affect cholesterol 
levels in man are not fully understood. The main route of cholesterol 
degradation is thought to be via its conversion to bile acids, but in 
man, hepatic cholesterol catabolism normally accounts for only 2 to 
5% of bile acid output (Dowling,1973). This is due to efficient 
reabsorption of bile acids during their enterohepatic circulation.
Cholesterol is synthesised by most animal tissues from acetyl-CoA. 
However, the bulk of endogenous plasma cholesterol is derived from 
the liver and secreted, with triglycerides, in VLDL. Lipolysis of 
VLDL in peripheral tissue is enhanced by the presence of apo-C 
(Levy et al,1976), which is removed during VLDL degradation. The 
delipidated VLDL particle is converted to LDL (Carlson,1976) which 
delivers cholesterol to peripheral tissues for renewal of cell 
membranes. It also inhibits the cellular synthesis of cholesterol 
by a feedback mechanism in the presence of apo-B (Brown et al,1976). 
Since most peripheral tissues cannot catabolise cholesterol, any 
excess must be transported to the liver if it is not to accumulate 
in the periphery.
Raised serum levels of both LDL and VLDL are atherogenic 
(Kannel et al,1971> Walton,1975)> but recently attention has been
diverted to serum HDL, which is inversely related to incidence of THD 
in younger populations (Gordon et al, 19-775 Miller et al,1977)« The 
origin of HDL and its function in lipid metabolism are not clear.
There is some biochemical evidence to show that apo-C, phospholipids, 
and possibly cholesterol are transferred to HDL during the catabolism 
of VLDL:
Following 60 minutes incubation of VLDL in vitro with lipo- 
protein-lipase-rich plasma (Eisenberg,1976) the apo-C in VLDL was 
reduced in proportion to the reduction in triglycerides. More than 
90^ of the apo-C molecules present in intact VLDL were transferred to 
HDL during the incubation. Although apo-C is present in human HDL 
in only small amounts, it does account for over one half of the total 
apo-C pool in normal fasting human plasma (Levy et al,1976). While 
there is no direct evidence, it is assumed that apo-C is not an 
integral part of the HDL structure, and forms an affinity with the 
surface constituents. It has been suggested that HDL serves as a 
reservoir for apo-C between tides of triglyceridaemia (Eisenberg 
et al,1972).
The transfer of phospholipids from VLDL to HDL is independent 
of the transfer of apo-C. In vitro experiments have shown that about 
60^ of the phospholipids are removed from VLDL during lipolysis 
(Eisenberg, 1976) and that this removal is chiefly due to hydrolysis 
of lecithin from VLDL to form lysolecithin. The latter is recovered 
in association with protein of very high density (above 1.21 gm/ml). 
Similarly, about 6CP/0 of the free cholesterol molecules are recovered 
in association with HDL (Larosa et al,197l)« This free cholesterol 
may then be esterified, by the LCAT system, with fatty acids released 
during hydrolysis of lecithin from VLDL, and associated with HDL.
Such a mechanism could therefore be involved in the clearance of excess
free cholesterol from the circulation, and hence in the maintenance 
of plasma cholesterol levels. As much as 4-6 gm per day of free 
cholesterol are released from VLDL and chylomicrons in human plasma 
(Glomset and Norum, 1973). However, the mode of clearance of 
esterified cholesterol from the circulation, as well as that of 
other HDL lipids, is not known. It has been reported that the fatty 
acid pattern of cholesterol esters in LDL resembles that of HDL 
(Faergeman and Havel, 1975) but Glomset (1968) hypothesised that 
transport of cholesterol from peripheral tissues to the liver, for 
catabolism, may be a function of HDL.
Some evidence supporting this hypothesis has been provided by 
in vitro experiments using a peripheral cell model system. Ehrlich
>7
ascites cells were labelled with H-cholesterol (Stein and Stein,1973)
and more label appeared in the medium following incubation with human
3
HDL than after LDL incubation. H-cholesterol-labelled skin fibro­
blasts were incubated for 24 hours with human HDL (Stein et al,1976) 
and about 30^ of the cellular label appeared in the medium. The 
cholesterol content of the cells was found to have fallen. Peripheral 
cells take up LDL more extensively than HDL in mammals and human HDL 
is "interiorised" very poorly. This would appear to be due to the 
presence on the cell surface of specific receptor sites (Brown and 
Goldstein,1974) which bind only lipoproteins containing apoprotein B 
(LDL and VLDL).
If the negative association which exists between serum HDL 
levels and arterial disease is a direct one, involving a protective 
role for HDL against lipid accumulation in arterial walls, then 
treatment which raises serum levels of HDL should protect against 
IHD. There is no such evidence available at present. Furthermore, 
little information about HDL levels is available for the aged, 
particularly in relation to IHD"; and the effects of treatment on
lipid metabolism in aged subjects has attracted little interest, 
despite the fact that two-thirds of the total deaths from I Hi) occur 
in the over 65*s.
In Chapter 3 it was shown that levels of cholesterol and tri­
glyceride in aged men were raised in those with clinical IHD. Since 
ascorbic acid treatment can reduce serum cholesterol levels in subjects 
with low ascorbic acid status (Ginter etaL,1970) and elderly patients 
in hospital are known to have low blood ascorbic acid levels (Griffiths 
et al,1967)j the following study examines the effects of ascorbic acid 
treatment on total lipid and lipoprotein levels in aged men and women. 
Results in controls were compared with those for patients with IHD, 
and with dysrhythmia-ischaemia. In addition, fasting glucose levels 
have been determined to exclude any effect on lipids of latent carbo­
hydrate intolerance.
LIPOPROTEIN AND GLUCOSE LEVELS IN AGED MEN AND WOMEN :
EFFECTS OF ASCORBIC ACID TREATMENT 
The Patients
Thirty-seven aged men and women in continuing care in hospital 
were selected for investigation in the absence of anaemia, valvar 
heart disease, a known myocardial infarction within the previous three 
months, and known possible causes of secondary hyperlipidaemia (Chait, 
1973; Table 4, p. 5^ ). As in the clinical study, the patients were 
divided into three groups following routine clinical examination and 
ECG (WHO,1959):
Group 1: 7 women and 7 men had no clinical or ECG evidence of
I HD or cardiac dysrhythm and acted as controls.
Group 2; 5 women and 6 men had a definite clinical history of
IHD and this was confirmed by ECG.
Group 3: 7 women and 5 men had ECG evidence of myocardial
ischaemia associated with supraventricular dysrhythmia.
Methods
1. Blood Sampling
Twenty-five ml hlood were withdrawn from each patient for initial 
analyses after a 14 hour overnight fast. Ascorbic acid, 1 gm daily, 
was given for a period of six weeks. At the end of this period, 
further fasting blood samples were withdrawn and the analyses repeated. 
The ascorbic acid dosage was tailed off to zero.
2. Lipoprotein Fractionation
Serum lipoproteins were separated by density using preparative 
ultracentrifugation, and the cholesterol and triglyceride in each 
fraction were estimated manually.
Preparative Ultracentrifugation (Adapted from De Lalla and Gofman,
1954)
Materials
MSE Superspeed 65 ultracentrifuge
(by Courtesy of Professor M.J.It.Smith, KCH)
10 x 10 ml aluminium angle rotor 
(by courtesy of MSE)
10 ml polycarbonate tubes with sealing cap assemblies 
(supplied by MSE)
Glass collecting tubes calibrated at 0.5 ml and 1 ml 
(specially made by Aimer Products Ltd., Rochester Place,
London,NWl)
Sodium chloride 1 .1 5 ° jo  solution (specific gravity 1.0074)
Sodium bromide 37.4^ solution (specific gravity 1.2690)
a) VLDL fraction (Density range 0.95 - 1.006 gm/ml)
Three ml fasting serum were placed in 10 ml polycarbonate tubes.
The volumes were made up to 7 ml by the addition of saline of specific 
gravity 1.0074. The tubes were weighed with their caps, and balanced 
in pairs prior to sealing, then sealed and placed in balanced positions 
in the rotor head. The rotor was centrifuged for 16 hours at 35>000 rpm 
(l00,000g) at 14°C.
The tubes were lifted carefully from the rotor and the caps 
removed. Each tube was clamped vertically under a bright lamp so 
that the supernatant VLDL could be seen as a distinct, translucent 
layer. This supernatant was carefully removed in 1.5 ml using a 
fine pasteur pipette and collected in prelabelled calibrated tubes.
The VLDL fractions were stored at 4°C prior to assay (within 2 days).
b) LDL Fraction (Density range 1.006 - 1.063 gm/ml)
The solutions remaining in the polycarbonate tubes were adjusted 
to a specific gravity of 1.064 by the addition of 1.5 ml sodium 
bromide solution, specific gravity 1.2690. This restored the volume 
to 7 ml. The tubes were reweighed with their caps, sealed, and 
centrifuged for a further 16 hours at 35>000 rpm.
The supernatant LDL was seen as a clear yellow layer and was 
removed carefully in 1.5 ml, collected in calibrated vials and stored 
briefly at 4°C.
c) HDL Fraction (Density range I.O63 - 1.21 gm/ml)
The remaining 5*5 ml consisted of a clear middle layer and a 
bottom yellow zone, which contained serum proteins and HDL. The whole
solution was stored at 4°C prior to assay.
The three separate fractions were then extracted for determination 
of triglyceride and cholesterol. All fractions from one specimen were 
analysed at the same time as the original serum, in order to calculate 
recovery. Results were expressed as mg cholesterol or triglyceride in 
fraction per 100 ml serum.
3. Cholesterol
Whole serum and fractions were extracted in ethanol/ether (75:25) 
and evaporated to dryness. Total cholesterol was determined by the 
Liebermann-Burchard reaction.
4. Triglyceride
After extraction in chloroform, triglyceride in whole serum and 
fractions was analysed by the method of Van Handel and Zilversmit 
(1957).
5. Glucose - Method of Hultman (1959) modified by Dubowski (1962)
This o-toluidine method is highly specific for glucose and simple
to perform, and compares favourably with enzymatic methods whose 
reagents are expensive and relatively unstable.
Glucose reacts with o-toluidine in glacial acetic acid in the 
presence of heat to yield a blue-green N-glueosylamine.
Materials
o-toluidine reagent (stabilised):
To 5*0 gm thiourea AR (Sigma), 90.0 ml o-toluidine (B.D.H.) 
were added. The mixture was diluted to 1 litre with glacial acetic 
acid, and stored in an amber glass dispenser at room temperature.
Glucose Standard - 100 mg/100 ml:
1.0 gm pure anhydrous dextrose (B.D.H.) was dissolved in 1 litre 
water containing 1.5 gm benzoic acid (Sigma). The solution was stored 
at 4°C and remained stable for one year.
Quality Control Serum (supplied by The National Quality Control 
Scheme, Wolf son Laboratories, Queen Elizabeth Hospital ,Edgbaston).
Easting plasma was separated from blood containing fluoride- 
oxalate as preservative and anticoagulant. Five ml o-toluidine reagent 
were transferred to 10 ml tubes. 0.1 ml standard (100 mg/100 ml) 0.1 ml 
quality control serum and 0.1 ml plasma were added to the appropriate 
tubes in replicate, and the solutions were mixed thoroughly by vortex. 
The tubes, including an o-toluidine blank, were placed in a boiling 
water-bath and stoppered. After 10 minutes the tubes were removed and 
cooled in a water-bath to room temperature.
The absorbances of the standards and unknowns were read against
the blank at 625 nm. The normal adult range for fasting plasma using 
this method is 70-100 mg/100 ml.
6. Ascorbic Acid in Plasma was measured by the method of Roe (l96l). 
Plasma was separated from oxalated blood soon after collection. A 
protein-free filtrate was obtained by the addition of TCA, and the 
ascorbic acid in the filtrate was oxidised to dehydroascorbic acid by 
mixing with charcoal. The supernatant may be stored at 4°C for 
several days prior to determination.
Dehydroascorbic acid was coupled with 2,4-dinitrophenylhydrazine 
to form 2,4-dinitrophenylosazone. This osazone was treated with strong 
sulphuric acid to form an orange complex, measured at 515 mn.
The normal range is 0.2 - 2.0 rng/lOO ml.
7. Ascorbic Acid in White Blood Cells was measured by the method of 
Denson and Bowers (1961). The homogenised deposit of white cells and 
platelets in TCA may also be stored at 4°C. The lower limit of normal 
was taken as 24 ^ ig/10^ WBC (Griffiths et al,1967),
8. Analysis of Results
Comparisons between results obtained for the controls and other 
patients were made by Student’s t-test. Comparisons between results 
obtained for the same patients before and after treatment with 
ascorbic acid were made by the paired t test. Correlation coefficients 
were determined where appropriate.
Since lipid levels vary with sex, the lipid results for men and 
women were analysed separately.
Results
The mean age of the nineteen female patients was 86 years 
(range 74 - 97 years). Eight of them were over 90 years old. The 
eighteen male patients had a mean age of 78 years (range 65 - 87 
years) (Figure 8) (For details see Appendix).
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Figure 8 Distribution of patients by age
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I Initial observations
l) LIPID LEVELS
Initial levels of cholesterol and triglycerides in whole serum 
and in the lipoprotein, fractions are shown in Table 6. Cholesterol 
levels in the lipoprotein fractions have also been expressed as mean 
percentages of total cholesterol (i.e. the sum of the percentages 
for each patient divided by the number of patients).
In all but two female patients the total cholesterol levels were 
below 250 mg/dl, the upper limit of normal for a younger population.
(a) Male and female controls
Although mean levels of total cholesterol and total triglyceride 
appeared to be greater in women than in men, the difference was not 
significant. However, the mean HDL-cholesterol level, the mean 
percentage cholesterol in the HDL fraction and the mean HDL-tri- 
glyceride level were significantly greater in women (p < 0.001;
p < 0.001; p < 0.01 respectively). The mean percentage cholesterol
in LDL was greater in men (p < 0.01).
(b) Patients with JLiJLU - Group 2
In men with .IHD, the mean total cholesterol level was greater 
than the mean for male controls, but the difference was not significant. 
VLDL-cholesterol was significantly greater (p <  0.02) and the mean 
percentage cholesterol in the HDL fraction significantly lower 
(p < 0.05), in the men with IHD.
Although no significant differences in cholesterol levels in any 
fraction were observed between women with IHD and female controls, the 
mean percentage cholesterol in HDL was lower in women with IHD (p <  0.05),
Total triglyceride and VLDL-triglyceride levels were greater in 
men with IHD than in male controls (p < 0.01; p < 0.01 respectively).
Total, VLDL- and LDL-triglyceride levels were elevated in women
TABLE 6 Mean Lipoprotein Levels in Three Groups of Aged Patients 
Before Ascorbic Acid Treatment
Group 1 Group 2 Group 3
(controls)
Men Women Men Women Men Women
Total cholesterol mg/dl 168 189 201 202 175 232
VLDL-cholesterol ” 15 19 27 22 19 19
LDL-cholesterol " 122 109 148 129 116 146
Cholesterol in LDL °/o 71 58 74 64 66 62
HDL-cholesterol mg/dl 31 59 26 48 38 60
Cholesterol in H D lP /o 18 32 13 23 22 27
Total triglyceride mg/dl 94 132 157 193 87 138
VLDL-triglyceride " 55 87 100 128 53 89
LDL-triglyceride ” 27 23 35 45 22 30
HDL-triglyceride ” 7 12 12 11 9 13
with HDD (p <  0.02; p <  0.05; P<0.05 respectively).
(c) Patients with dysrhythmias - Group 5
Mean levels of cholesterol and triglyceride in whole serum or in 
the lipoprotein fractions did not differ significantly from the means 
found in controls, for either men or women. However, the highest total 
cholesterol levels were found in two women with dysrhythmias (G.W. 
and M.S.), who had levels of 329 mg/dl and 277 mg/dl.
2) RELATION BETWEEN HDL-CHOLESTEROL AND SERUM LIPIDS
In men, HDL-cholesterol was not correlated with total serum 
cholesterol or triglyceride levels.
In women, HDL-cholesterol was negatively correlated with total 
and VLDL-triglyceride levels (p < 0.05; P <  0.05) (Figures 9 and 10) 
hut was not correlated with total cholesterol.
3) FASTING GLUCOSE LEVELS
All patients had fasting glucose levels within the normal range
(see page 69). No differences were observed between means for the
three groups of patients (Table 7)*
TABLE 7 Fasting Glucose Levels (Mean +_ S.E.) Before and After 
Ascorbic Acid Treatment
Initial Glucose 
mg/dl
Group 1 (controls) n = 14 83 ,+ 2
Group 2 n = 11 79 +, 3
Group 3 n = 12 87 +. 3
II Effects of Ascorbic Acid Treatment
l) BLOOD ASCORBIC ACID LEVELS
Plasma ascorbic acid levels (measured in all 19 women and 11
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in aged women
of the men) and WBC-ascorbic acid levels (measured in all 37 patients) 
before and after ascorbic acid treatment for 6 weeks are shown in 
Table 8.
TABLE 8 Mean Plasma and WBC-Ascorbic Acid Levels Before and After 
Treatment
Men Women
Initial Final Initial Final
Plasma-AA mg/dl 0.15 0.71 0.29 1.04
WBC-AA /ig/lO8 WBC 23 32 23 35
In fifteen out of thirty patients, initial plasma ascorbic acid 
levels were below 0.2 mg/dl (lower limit of normal range - see page 69) 
In 22 of the 37 patients WBC-ascorbic acid levels were below the
g
accepted minimum of 24 /Ug/l0 WBC. No significant differences were 
observed between means for the men and those for the women, of either 
plasma or WBC ascorbic acid.
Following six weeks administration of 1 gm ascorbic acid daily, 
levels in plasma and WBC in each patients were within the normal ranges
2) LIPID LEVELS
(a) All patients
For all 18 male patients, six weeks treatment with ascorbic acid 
was associated with a significant rise in the mean levels of HDL 
cholesterol, from 3 1 + 2  mg/dl to 38 £  2 mg/dl (+ SEM: p < 0.001).
No significant changes were observed in mean total, LDL- and VLDL- 
cholesterol levels or in levels of triglyceride in whole serum and 
fractions.
For all 19 female patients, no significant changes were observed.
(b) Control group
In men, the only significant change was a rise in HDL-cholesterol
(p <  0.05) (Table 9). No significant changes occurred in the female 
controls,
TABLE 9 Mean Lipoprotein Levels After Ascorbic Acid Treatment
Group 1 Group 2 Group 3
Men Women Men Women Men Women
Total cholesterol mg/dl 188 192 176* 230 160 235
VLDL-cholesterol " 16 15 21 19 18 18
LDL-cholesterol 11 150 114 125* 154 100 159
HDL-cholesterol tt 37* 57 34* 58* 42 60
Total triglyceride ft 101 133 134 141* 92 136
VLDL-triglyceride !l. 63 89 87 93* 62 85
LDL-tr i gly c er i de ,! 25 24 31 35 19 29
HDL-tr i gly c er i de " 8 12 10 9 9 12
* = significant change from initial values
(c) Patients with IHD - Group 2
In men, total and LDL-cholesterol levels were significantly lower 
(p <  0,05; p <  0,05) after ascorbic acid treatment. The mean HDL- 
cholesterol level rose significantly (p < 0,02), Deductions in total 
and VLDL-tri glycerides were not significant.
In women with IHD, no significant changes were observed in mean 
levels of total and LDL-cholesterol, HDL-cholesterol, however, was 
increased (p < 0,05) and total and VLDL-triglyceride levels were 
reduced (p < 0,01; p < 0,05 respectively) after six weeks,
(d) Patients with dysrhythmias - Group 5
No significant changes were observed in mean lipid levels in 
either men or women. However, one womian in this group, whose initial 
cholesterol level was the highest recorded in this study, had a final 
level within norjnal limits (Table 10), Her triglyceride level 
responded less effectively.
Pl
as
am
 
AA
 
mg
/d
l 
WB
C 
AA 
ug
/l
O 
WB
C
40
30
00
oo
°o
o o20
10
r = 0.70
60 8040200
HDL-chol mg/dl
Figure 11 Relation of WBC-ascorbic acid to HDL-cholesterol 
in men
0,6
0.4
0.2
r = 0.69
403020100
HDL-TG mg/dl
Figure 12 Relation of plasma ascorbic acid to HDL-triglyceride 
in men
WB
C-
AA
 
ug
/l
O 
WB
C
40
30
20
_ °  oo o
oo
10
r =
J________ I________I________!________ L
10 20 30 
HDL-TG mg/dl
0.50
 !_________ I
40
Figure 13 Relation of WBC-ascorbic acid to HDL-tri- 
glycerides in women
TABLE 10 Lipid Changes in One Female Patient (G.W.) After 
Ascorbic Acid Supplements
Before After
Supplements Supplements
Total cholesterol mg/dl 329 247
VLDL-cholesterol " 36 27
LDL-cholesterol ” 233 150
HDL-cholesterol *' 62 76
Total triglyceride ” 233 198
VLDL-triglyceride ** 158 133
LDL-triglyceride ** 45 35
HDL-triglyceride 11 19 21
3) RELATION OF INITIAL LEVELS OF ASCORBIC ACID WITH LIPID LEVELS 
In men, significant positive correlations were observed between
WBC-ascorbic acid and HDL-cholesterol levels (n = 18, p < O.OOl) and 
between plasma ascorbic acid and HDL-triglyceride levels (n = 11,
P < 0.02).
In women, there was a correlation between WBC ascorbic acid and 
HDL-triglyceride (n = 19> p <  0.02) (Figures 11-13),
No correlations were observed between initial ascorbic acid and 
cholesterol or triglyceride levels in whole serum, VLDL and LDL.
4) EFFECTS ON FASTING GLUCOSE LEVELS
After six weeks* ascorbic acid treatment, mean fasting plasma 
glucose levels remained unchanged (Table 7),
Discussion
The cholesterol and triglyceride levels found in the aged control 
patients were very low, supporting the results for aged men in Chapter 
3 and the findings of Danner and colleagues (1978) for nonagenarians 
in Amsterdam. While HDL-cholesterol concentrations in the present 
series of female controls were similar to values found in younger, 
healthy women, HDL-cholesterol levels in the aged men were lower than
those reported in younger men (Table 11).
Women are relatively immune to IHD before the age of 40, after
the
whichyincidence steadily increases (Kannel and Dawber,1972). Serum 
lipid levels in women rise following the menopause (Wood et al,1972) 
and the present study shows that in aged women there is a significant 
relationship between clinical IHD and serum triglycerides, but not 
cholesterol. The highest cholesterol levels were found in two 
women with dysrhythmias, suggesting a multiple pathology in these 
patients. This is similar to the findings in aged men with dysrhythmias 
reported in Chapter 3*
The mean HDL-cholesterol value in aged women was significantly 
greater than that for the aged men, supporting the findings of others 
(Carlson and Ericsson,1975; Gordon et al,1977) that HDL-cholesterol 
is higher in women at all ages. These higher levels may protect women 
against the earlier development of IHD. Low HDL-cholesterol is a risk 
factor for future coronary heart disease in younger patients (Gordon 
et al,1977> Miller et al,1977)j and HDL-peptide levels are lower in 
middle-aged male survivors of myocardial infarction than in healthy 
controls (Berg et al,1976a). In the aged male and female patients 
with IHD, HDL-cholesterol as a percentage of total cholesterol was 
significantly lower than in controls; while mean VLDL-triglyceride 
levels were significantly greater.
It has been shown in younger people that HDL-cholesterol levels 
are inversely proportional to total triglyceride (Gordon et al,1977? 
Schaefferet al,1978) and to VLDL-triglyceride levels (Carlson,I973; 
Anderson, 1978). Although there were no correlations for the aged men, 
HDL-cholesterol was inversely related to both total and VLDL-tri- 
glyceride in the aged women. This may reflect the transfer of free 
cholesterol from VLDL to HDL during lipolysis (Larosa et al,1971) and
Table 11 Lipid levels reported in other investigations compared 
with levels found in present study
Total HDL- Total
cholesterol cholesterol triglyceride 
mg/dl mg/dl mg/dl
M F M F M F
Investigation, age group (yrs.)
Miller et al (1977) 37-49 229 39 165
“ ickson et al (1967) 240 2 ^  47 ^  104
C6^ 69n & 11171088011 (1975) 251 287 56 69 161 162
Gordon et al (1977) 70-79 - 47 55 117 126
Danner et al (1978) 90+ 181 205 47 53 92 119
Present study:
Control patients 168 189 31 59 94 132
Patients with I HD 201 202 26 48 157 193
a transfer of apoprotein C to HDL proportional to the lipolytic 
reduction in VLDL-triglyceride (Eisenberg,1976).
In younger people, ascorbic acid treatment has been shown to 
reduce serum cholesterol levels in healthy subjects under 25 years 
(Spittle,1971) and in hypercholesterolaemic subjects with low initial 
blood ascorbic acid levels (Ginter et al,1970), although no effect 
was detected in hypercholesterolaemic subjects with normal ascorbic 
acid status (Peterson et al,1975)« It is possible that ascorbic 
acid administration is only effective if the tissues are not saturated 
with the vitamin.
In the present series of aged patients, ascorbic acid status was 
low, but only 2 female patients were overtly hypercholesterolaemic.
Daily gram-dOses were associated with a reduction in serum cholesterol in 
one of them, and a significant reduction in cholesterol in the group of 
men with IHD. However, HDL-cholesterol was significantly increased in 
both men and women with IHD, and in men as a whole. Furthermore, initial 
WBC ascorbic acid levels were positively correlated with HDL-cholesterol 
in men, but not with total cholesterol, supporting similar findings in 
elderly men living at home by Bates and colleagues (1977)* Triglyceride 
levels were reduced in women with IHD, who had raised initial levels, 
and similar effects have been reported in younger hyperlipidaemic 
patients (Sokoloff et al,1966) together with an increase in lipoprotein 
lipase activity. Since fasting glucose levels were normal in all 
patients, and the effect of ascorbic acid in reducing triglyceride 
levels was not associated with any change in glucose concentration, 
it seems unlikely that hypertriglyceridaemia in these patients was 
associated with latent glucose intolerance, i.e. an insulin effect.
Ascorbic acid may have an effect on more than one of the mechanisms 
regulating lipid metabolism. In the guinea pig there is evidence that 
ascorbic acid stimulates the catabolism of cholesterol to bile acids
mediated by an effect on cytochrome (GtBt01,> 1973) j but this
mechanism may not be relevant in man. Raised levels of fasting 
triglyceride can be due to an increase in secretion of VLDL, as 
well as to a defect in clearance of VLDL-triglyceride (Kaye and 
Galton,1975). Moreover, the activity of lipoprotein lipase is 
influenced by insulin, catecholamines, ACTH and glucagon.
The most consistent effect of ascorbic acid in these aged 
patients was an increase in HDL-cholesterol. This may be partly due 
to an effect on lipoprotein lipase activity, although not all patients 
whose HDL-cholesterol was affected showed reciprocal changes in tri­
glyceride levels. Another possibility is an effect on the enzyme 
LCAT.
It is apparent from the results that even in very old age, 
clinical I Hi) is associated with disorders of lipoprotein metabolism. 
These disorders may be a residual effect of a process which began 
earlier in life; nevertheless, the changes in lipoprotein levels 
following ascorbic acid treatment suggest that in some individuals, 
earlier attention to ascorbic acid in the diet may have a role in 
preventing, or retarding, the development of IHD.
CHAPTER 5
THE LECITHIN-CHOLESTEROL ACYL TRANSFERASE 
(LCAT) REACTION
The plasma cholesterol "esterifying enzyme" was first recognised 
by Sperry (1935) who observed an increase in esterified cholesterol 
during the incubation of serum or plasma. He suggested that the 
fatty acids might be derived from plasma phospholipid by the action 
of a lipase, but later postulated the existence of a special 
cholesterol-esterifying enzyme in man (Sperry and Stoyanoff,1938). 
Evidence that plasma phospholipids were the source of fatty acids in 
the esterification reaction was obtained by Le Breton and Pantaleoh 
(1947) and a mechanism was proposed which involved the action of a 
lecithinase coupled with a cholesterol esterase:
LECITHIN -1--ltb^nase ^  2 FATTY ACID + GLYCEROPHOSPHORYL CHOLINE
CHOLESTEROL + FATTY ACID . .cbo^Gst.eyoL ,cs.t.9.raSG > CHOLESTERYL ESTER
Subsequently Glomset (1962) obtained evidence to suggest that 
the initial breakdown of lecithin was not catalysed by a hydrolase, 
but by an acyl transferase, and noted that incubation of human plasma 
produced a molar change in lecithin similar to that in unesterified 
cholesterolo The following mechanism was postulated:
LECITHIN + UNESTERIFIED CHOLESTEROL J ^ ^ .a~ eTas%  LYSOLECITHIN +
CHOLESTERYL ESTER
It was suggested that the enzyme transfers a fatty acid from the 
p-position of lecithin to the hydroxyl group of free cholesterol.
Further work showed that human, acyltransferase reacts preferentially 
with specific lipoproteins. After 1 hour*s incubation of human plasma
with labelled cholesterol, the specific activity of HDL cholesteryl 
esters greatly exceeded that of VLDL or LDL cholesteryl esters 
(Glomset,1968). Calculations indicated that four times as much HDL- 
cholesterol was esterified as LDL-cholesterol and, moreover, the 
calculations did not account for the non-enzymic transfer of newly 
formed cholesteryl esters from HDL to LDL and VLDL (Nichols and Smith,
1965).
Unesterified cholesterol probably transfers to HDL from both 
cells and lipoproteins after HDL cholesterol esters have been formed 
by LCAT, and much of the lysolecithin formed during the reaction moves 
away from the lipoproteins and is bound to albumin (Switzer and Eder, 
1965)* The effects of the reaction on lipoproteins are difficult to 
test in normal subjects, in whom the metabolism of triglyceride and 
cholesterol in plasma are well integrated.
The importance of the LCAT reaction was eventually recognised 
when Norum and Gjone (1967) described an inborn error of metabolism 
characterised by the absence of acyltransferase activity. In the 
small group of patients in whom LCAT deficiency has so far been 
recognised (Norum et al,1972) the disorder appears to be inherited 
as an autosomal recessive gene. The disorder results in a deficiency 
of normal HDL, the near-absence of esterified cholesterol in the plasma 
and a raised lecithin/lysolecithin ratio. In five of six patients 
described, both total cholesterol and triglyceride levels have been 
raised. The disc-shaped lipoproteins in the LDL and HDL density 
ranges,containing large amounts of free cholesterol and lecithin, 
may form as fragments of chylomicrons and VLDL when triglyceride 
is removed by the lipoprotein lipase reaction (Glomset,1976).Clinical 
features include proteinuria, anaemia, and corneal arcus. Work 
involving incubation of the patients* plasma in vitro with LCAT has
shown that the effects of LCAT are complex, and involve the apo­
proteins (Norum et al,1975)« Apoprotein A may act as a carrier of 
esterified cholesterol from HDL to VLDL. LCAT is synthesised in 
the liver (Glomset and Norum, 1973)> circulates in plasma in association 
with HDL, and is possibly activated by the A group of apoproteins 
(Levy et al,1976).
Although esterified cholesterol is transferred from HDL to the 
lower density lipoproteins, the cholesterol ester content of newly 
secreted VLDL adequately accounts for the cholesterol ester content 
of its metabolite, LDL. The LCAT reaction thus may be involved with 
the removal of excess unesterified cholesterol and lecithin from the 
circulation, rather than with the supply of esterified cholesterol to 
lower density lipoproteins. The possibility that LCAT has a role in 
the transport of cholesterol from peripheral tissues to the liver, 
and in membrane homeostasis, was suggested by Glomset (1968). Serum 
was incubated at 37°C for 24 hours, after which erythrocytes were 
added. A net transfer of unesterified cholesterol from the erythro­
cytes to the serum occurred (Murphy,1962) and the loss of erythrocyte 
cholesterol was related to the amount of esterified cholesterol formed 
in the serum during the preincubation. This loss may have been due to 
a shift in equilibrium of unesterified cholesterol between the 
erythrocytes and lipoproteins, produced by the esterification reaction.
Since the unesterified cholesterol of most peripheral tissues 
appears to be in equilibrium with that of the plasma lipoproteins, 
the following was postulated, illustrated in Figure 14:
HDL and LCAT enter the interstitial fluid of peripheral tissue; 
lipoprotein cholesterol is esterified by the LCAT reaction; un­
esterified cholesterol passes to HDL from cell membranes; the lipo­
proteins re-enter the plasma via the lymph, releasing their excess
cell
membrane
HDL
Uptake of • 
from membrane 
by physical 
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liver
I
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Figure 14 Postulated mechanism for the transport of 
cholesterol from peripheral cell membranes 
to the liver
(adapted from Glomset,1968).
cholesterol in the liver.
The LCAT reaction, or the esterification of cholesterol, has been 
measured by three types of method. In the first, serum or plasma is 
incubated for 1-3 days at 37°C, and the change in unesterified 
cholesterol is determined. However, this method essentially measures 
the extent of esterification rather than the rate, and depends more 
upon the amount of substrate available than upon the level of enzyme 
activity. In the second method, serum is incubated for 1-3 hours at 
37°C, and the initial rate of change in unesterified cholesterol is 
determined. This method depends upon the level of enzyme activity 
and also upon the availability of the substrate. Thus, it can be used 
to estimate the rate of esterification of cholesterol in vivo, but not 
to determine the actual activity of the enzyme.
In the third method, a relatively small amount of fresh plasma 
is incubated at 37°C with a substrate consisting of heat-inactivated 
plasma and labelled, unesterified cholesterol. The formation of 
labelled cholesteryl esters is measured. It is assumed that the 
labelled, unesterified cholesterol has equilibrated with the unlabelled, 
unesterified cholesterol in the lipoproteins. The labelled cholesterol 
is a highly sensitive indicator of esterification, enabling small 
quantities of fresh plasma (enzyme source) to be used. The principle 
variable in the determination of enzyme activity is thus the level 
of enzyme; nevertheless, the method is not completely independent of 
endogenous substrate, and facilities for radioassay are not always 
available.
In Chapter 4 it was shown that ascorbic acid treatment was 
associated with changes in lipoprotein levels in some aged patients, 
and in particular, with increases in HDL-cholesterol. The latter may 
be associated with an effect of ascorbic acid on the rate of cholesterol
esterifying activity in serum. The following study examines this
I
possibility in a small number of aged men and women, using the second 
type of method described to measure the rate of esterification.
Effects of Ascorbic Acid Treatment on Cholesterol-Esterifying
Activity in Aged Patients
Patients
Nineteen aged men and women in continuing care were selected and 
divided into three groups as in Chapters 3 aud 4. Two men and four 
women acted as controls (Group l), four men and three women had 
clinical and ECG evidence of IHD (Group 2) and three men and three 
women had evidence of myocardial ischaemia associated with dysrhythmia 
(Group 3).
Methods
1. Blood Sampling
Easting blood was withdrawn and the serum separated for analysis 
of HDL-cholesterol and whole serum free cholesterol. Serum for the 
latter was deep frozen prior to assay. Ascorbic acid, 1 gm daily, 
was given to each patient for six weeks, after which time the analyses 
were repeated.
2. HDL-Cholesterol
The HDL fraction was separated as in Chapter 4, and the cholesterol 
was estimated manually.
3. Rate of Cholesterol Esterification in Serum
Changes in free (unesterified) cholesterol were measured by a 
sensitive enzymatic method.
Materials
"Merckotest’1 kit for enzymatic determination of free and total 
cholesterol: Merck No.14350 (supplied by BDH Chemicals,Poole,Dorset) 
containing: colour reagent with potassium iodide and detergent 
buffered at pH 6.2; cholesterol oxidase solution; cholesterol 
esterase (added only for measurement of total cholesterol).
SMI Micro-Pettor positive displacement pipette - 10 yul (supplied 
by Alpha Laboratories,Greenford).
’’Preciset" cholesterol standards in aqueous solution (supplied 
by Boehringer,Lewes,Sussex).
Principle
Free and esterified cholesterol are released by detergents from 
lipoproteins. Cholesterol oxidase releases hydrogen peroxide from 
free cholesterol. The hydrogen peroxide converts iodide in the reagent 
solution to iodine, which is measured photometrically.
Procedure
Serum from each patient was divided into two 1 ml portions. One 
portion was deep frozen. The other was incubated at 37°C for 3 hours 
and immediately frozen prior to assay. One ml cholesterol oxidase 
solution was added to 80 ml colour reagent and mixed thoroughly.
This reaction solution was stable for 1 month at 4°C.
Ten yul of standard, incubated serum and unincubated serum were 
placed in duplicate in 5 ml vials. Two ml reaction solution were 
added to each vial and the contents mixed thoroughly. The solutions 
were incubated at room temperature for 30 minutes, and the absorbances 
read against a reagent blank at 365 um. The rate of cholesterol 
esterification was thus determined by the difference in free cholesterol 
in the pre-incubated and unincubated serum samples.
4. Analysis of Results
Comparisons of initial rates of cholesterol esterification 
between the three groups of patients and between aged men and women 
were made by Student*s t test. Comparisons of rates of cholesterol 
esterification before and after ascorbic acid treatment in the same 
patients were made by the paired t test. To determine whether the 
effects of ascorbic acid on HDL-cholesterol were associated with
effects on the rate of cholesterol esterification, the correlation 
coefficient was estimated between changes in HDL-cholesterol and 
changes in rate of esterification following six weeks ascorbic acid 
treatment.
Owing to the limited number of patients available for study, it 
was not possible to compare results between the three groups for men 
and women separately.
Results
I Initial Rate of Cholesterol Esterification
1) Men versus Women
No significant difference was observed between the mean rate of 
esterification for the men and the mean for the women (Table 12).
2) Group Differences
No significant differences were observed between the mean rate 
of esterification for the control group and the mean for patients 
in Group 2 or patients in Group 3.
TABLE 12 Mean (+ SE) Rates of Cholesterol Esterifying Activity 
in Aged Patients Before and After Ascorbic Acid
Rate of Esterification jug/ml/hr. 
Initial Final
All men (n = 9) 5*3 +  1*3 5.6 ±  2.3
All women (n = 10) 7*7 +; 2.5 9*9 +, 2.4
Group 1 - controls (n = 6) 3.8 _+ 2.0 3*2 Hh 1.2
Group 2 — IHD ( n = 7 )  7.9 +. 1.8 8.4 £  2.1
Group 3 - dysrhythmia (n = 6) 7*8 + 3.5 11.8 4.3
Change in
esterification
rate
/ig/ml/hr o
-4 8 12 
Change in HDL-chol mg/dl
-4
0.74-8
-12
Figure 15 Regression of change in rate of esterification 
with change in HDL-cholesterol in aged men
II Effects of Ascorbic Acid
1) In Men
In the 9 men studied, the mean rate of esterification was not 
significantly different after six weeks ascorbic acid treatment 
(Table 12). The changes in rates of cholesterol esterification after 
ascorbic acid treatment were positively correlated with changes in 
HDL-cholesterol levels (r = 0.7432, p <  O.Ol) (Figure 15).
2) In Women
In the 10 women, ascorbic acid treatment had no significant effect 
on the mean rate of esterification. No significant correlation was 
observed between changes in rates of esterification and changes in 
HDL-cholesterol levels (r = 0.3540).
3) Within Groups
In the control group, no significant effects were observed upon 
the mean esterification rate and changes in rates of esterification 
were not correlated with changes in HDL-cholesterol.
In Group 2 (patients with Ml)) there was no significant change 
in the mean rate of esterification. Changes in HDL-cholesterol levels 
were not significantly correlated with changes in rates of esteri­
fication (r = 0.4090),.but mean HDL-cholesterol rose significant ly (p<0.0l) 
In Group 3 (patients with dysrhythmias) no significant changes 
were observed in the mean esterification rate. Furthermore, changes 
in rates of esterification and in HDL-levels were not significantly 
correlated (r = 0.6422).
Discussion
The mean rates of cholesterol esterification in aged men and 
women did not differ significantly, supporting the findings of 
Gherondache (1963) who reported no sex difference in the extent of 
cholesterol esterification in the sera of younger men and women.
There were no significant differences between the mean rate of 
esterification for the control group and the means for patients with 
■LHP or those with dysrhythmias; moreover, ascorbic acid treatment had 
no significant effect on the mean rates of esterification in either 
male or female patients, nor in any of the three clinical groups. 
However, ascorbic acid treatment was associated with an increase in 
the mean HDIr-chol ester ol level for all the men, and for the group of 
patients with JHD, thus supporting the findings in Chapter 4. Further­
more, in men, changes in HDL-cholesterol levels were significantly 
correlated with changes in rates of esterification following ascorbic 
acid treatment.
These findings suggest that ascorbic acid does not have a direct 
effect on LCAT activity, although the number of patients available 
for study was small, and the method used did not measure the level 
of enzyme activity per se. Schumaker and Adams (1970) postulated 
that lipoprotein lipase and LCAT act in tandem in the catabolism of 
chylomicrons and "VLDL. Lipoprotein lipase catalyses the hydrolysis 
of the triglyceride component, and the remnant free cholesterol and 
lecithin are removed by the LCAT reaction - thus increasing the 
cholesteryl ester content of HDL. Hence the rate of esterification 
by LCAT is dependent partly upon the availability of substrates 
released during catabolism of VLDL. Indeed, exogenous lecithin 
markedly increases cholesterol esterification in vitro, suggesting 
that the availability of endogenous lecithin in plasma is an 
important factor. However, the rate of esterification in fresh plasma 
decreases before the lipoprotein content of lecithin is exhausted 
(Glomset,1968). Thus, only a limited amount of lipoprotein lecithin 
can serve as a donor of fatty acids - the amount released from its 
structural role during catabolism of triglycerides. Such a sequence
in lipoprotein metabolism could account for the related changes in 
HDL-cholesterol levels and rates of esterification in men following 
ascorbic acid treatment, whereby ascorbic acid may have a direct 
effect on lipoprotein lipase activity (Sokoloff et al,1966) and 
hence an indirect influence on the availability of free cholesterol 
for esterification.
CHAPTER 6
THE EHEOLOGIST1S VIEW
The primary defect in 1HJ) is that hlood flow to the myocardium 
is inadequate for its oxygen requirements. Not only is the rate of 
blood flow important as a primary factor in THT) but the rate and 
pattern of blood flow can also influence the site, growth and 
dissolution of arterial thrombi. In areas of very high shear (flow 
rate) the arterial endothelium can be dislodged (Fry, 1969) exposing 
the subendothelial collagen to which,platelets adhere (Mustard and 
Packham, 1970). Blood flow can influence the number of platelets 
which adhere to the damaged vessel wall and the shearing effect of 
flow can dislodge a platelet thrombus which has formed (Mustard et 
al,1964). At a point of narrowing in an artery (for example, at the 
site of an atherosclerotic plaque), the disturbed pattern of blood 
flow can facilitate the accumulation of platelets, and arterial 
thrombosis is rare except in arteries with atherosclerotic narrowing 
(Baroldi,1976; Mustard,1977)• Thus, blood flow can influence the 
development of thrombi in atherosclerotic vessels in two ways: by
altering the vessel wall and by determining the site and size of the 
thrombus. In circumstances in which mural thrombi form in an area 
of disturbed flow, the thrombus may not grow to an occlusive mass 
but will fragment, with the platelet-fibrin emboli passing into the 
distal circulation. Such emboli can cause transient cerebral 
ischaemia (Torvik and Jorgensen,1966) so could possibly cause 
transient attacks of myocardial ischaemia; and if entering the 
micro-circulation serving the specialised conducting tissue, the 
emboli could produce fatal arrhythmias. Such a mechanism has been 
demonstrated in pigs (Jorgensen et al,1967) with ADP-induced 
platelet aggregates in the myocardial circulation.
The rate of blood flow is determined by three variables - the 
radius of the vessels, the pressure gradient, and the viscosity of
the blood. While atherosclerotic narrowing is usually the under­
lying lesion in thrombotic occlusion of the femoral artery, causing 
ischaemia of the limb (Wessler et al,1958), attention was drawn to 
the importance of viscosity in reducing blood flow in peripheral 
ischaemia (Dormandy et al,1973). Patients with intermittent claudi­
cation had a significantly higher blood viscosity than controls, at 
both low and high shear rates. A 10^ increase in blood viscosity 
was associated with a decrease of over 20°/o in total blood flow through 
a lower limb (Dormandy, 1971 )• Further work showed that many of the 
patients with abnormally high blood viscosity and severe symptoms of 
claudication had normal arteriograms (Dormandy et al,1974). In these 
cases, the abnormal blood viscosity may represent the principal 
aetiological factor, while in others it may coexist with some degree 
of arterial narrowing. About 25-30°/o of moderate to severe claudicants 
had an abnormally high blood viscosity and the concept of "rheological 
claudication" was suggested for these patients. Similar rheological 
factors may be involved in those patients with symptoms of IHD without 
any evidence of coronary arterial disease (Richardson et al,1974).
Blood viscosity was significantly higher in patients with angina 
pectoris than in normal controls (Nicolaides et al,1977) and the 
raised blood viscosity was associated with higher haematocrit levels. 
Similarly,cerebral blood flow was found to be reduced in patients 
with raised haematocrit values (Thomas et al,1977). An improvement 
in flow was obtained by reducing the haematocrit and hence the blood 
viscosity. The haematocrit, or packed cell volume, is the most critical 
determinant of whole blood viscosity except in the micro-circulation.
The influence of haematocrit on blood viscosity falls steadily with 
decreasing vessel bore (Prothero and Burton,1962; Jay et al,1972).
Other factors affecting blood viscosity are erythrocyte flexibility,
and plasma protein and fibrinogen concentrations. A raised plasma 
fibrinogen was the commonest biochemical abnormality in patients with 
intermittent claudication (Dormandy et al,1973) and plasma fibrinogen 
levels correlated positively with blood viscosity (Dormandy et al, 
1974) and plasma viscosity (Stormer et al,1974). Reduction of plasma 
fibrinogen and blood viscosity by the administration of clofibrate 
produced a clinical improvement in some patients with claudication 
(Postlethwaite and Dormandy, 1975)*
Since patients with angina pectoris also had raised fibrinogen 
levels compared with controls (Nicolaides et al,1977) it was suggested 
that the clinical improvement observed in previous studies when 
patients with angina were treated with clofibrate (Dewar and Oliver, 
1971) may have been the result of reducing fibrinogen levels and 
hence increasing coronary perfusion.
The mechanisms regulating hepatic synthesis of fibrinogen and 
homeostasis are poorly understood. Pickart and Thaler (1976) 
proposed a scheme for in vivo regulation of fibrinogen synthesis after 
its depletion by clotting mechanisms (Figure 16). Thrombin enhances 
fibrinogen synthesis in intact animals, but has no direct effect on 
the liver in vitro, while free fatty acids increase fibrinogen 
synthesis in isolated mouse liver slices in the absence of thrombin.
It was postulated that the production of fibrin degradation products 
after clotting potentiates the effects of circulating epinephrine on 
mobilising free fatty acids from adipose tissue. Plasma fibrinogen 
concentration did not itself influence fibrinogen synthesis (Alving 
et al,1977).
Plasma fibrinogen levels influence blood viscosity both by a 
direct effect on plasma viscosity and by increasing red cell 
aggregation or rouleaux formation (Dintenfass,1975) by macro-molecular
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bridging (Chien et al,197l). The latter effect may explain the 
variation of blood viscosity with shear rate. Whole blood resembles 
a non-Newtonian fluid exhibiting a non-linear relationship between 
shear rate and viscosity. At low shear rates the relationship depends 
upon the degree of erythrocyte aggregation, and the viscosity is 
higher than at fast shear rates owing to the energy utilised in 
breaking the weak interactive forces between cells.
Older patients are less able to maintain cerebral blood flow in 
the presence of a raised blood viscosity (Thomas et al,1977). The 
maintenance of flow in such circumstances would involve an increase 
in blood pressure and cardiac work load, or a reduction in peripheral 
resistance by vasodilation. These compensatory mechanisms become 
less efficient with age. The effects of viscosity on coronary blood 
flow in aged subjects may contribute to myocardial ischaemia, but 
there is no such information available at present.
Opportunity was taken to investigate the importance of rheological 
findings in aged patients with IHD, and those with myocardial ischaemia 
associated with dysrhythmias.
Blood Viscosity, Haematocrit and Plasma Fibrinogen in Aged Patients 
with IHD 
The Patients
Aged patients in continuing care were selected and divided into 
three groups following clinical and ECG assessment as described in 
Chapters 3 and 4.
Blood viscosity and haematocrit were measured in 19 patients of 
whom six acted as controls (Group l), seven had evidence of IHD 
(Group 2) and six had evidence of myocardial ischaemia associated 
with dysrhythmias (Group 3). Plasma fibrinogen was measured in these 
patients and also in 29 of the aged patients described in Chapter 4.
Blood samples were collected in EDTA bottles and analysed before and 
after six weeks1 administration of ascorbic acid, 1 gm daily.
Methods
1. Blood Viscosity (procedure of Mr.J.A.Dormandy,St.James* Hospital,
SW12)
MATERIALS
Wells-Brookfield Micro Viscometer (supplied by Baird and Tatlock 
Ltd., PO Box 1, Romford,Essex)
Standard Newtonian Oil - 5 centipoises calibrated at 25°C 
(supplied by Baird and Tatlock Ltd.)
PRINCIPLE
The Wells-Brookfield Micro Viscometer was originally developed 
to investigate the rheological characteristics of biological fluids 
of a non-Newtonian nature, and operates at four shear rates. The 
temperature is controlled by a water jacket around the sample cup.
An obtuse cone is rotated at constant speed (shear rate) on a flat 
plate (Figure 17) which forms the bottom of the sample cup. A precise 
torque measuring device connects the driving mechanism of the visco­
meter to a vertical shaft from which the cone is suspended. A small 
sample of fluid between the cone and plate offers a resistance to 
the rotation of the cone which develops a torque related to the shear 
stress and viscosity of the fluid. The degree of deflection is read 
from a dial and converted to centipoise units of viscosity.
PROCEDURE
The viscometer was levelled when operating in air at 12 rpm.
The plate (sample cup) was attached, and the micrometer ring adjusted 
until the apex of the cone just cleared the surface of the plate, 
and the dial needle came to rest at zero when rotation was stopped.
One ml standard Newtonian oil was placed in the plate, and the visco­
meter was calibrated at 6 rpm (shear rate 23 secs )^ and 60 rpm (shear
shaft
cone v.
T
Shear stress (dynes/cm^) = ^ ^ 3
-1 —
Shear rate (sec ) = g^n Q
Viscosity _ Shear stress x 100 
(centipoise) Shear rate
where T = °fo full scale torque (dyne-cm)
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Figure 17 Section of micro viscometer showing relation 
of cone and plate
rate 230 secs ^). The plate aad cone were then cleaned with acetone 
and water, and dried with tissue.
Blood anti coagulated with EDTA was kept in suspension by mixing. 
One ml blood was ejected into the plate, avoiding bubble formation 
and ensuring that the pipette tip did not scratch the surface. The 
plate was re-attached to the viscometer and a speed of 6 rpm selected. 
After rotation for exactly 2 minutes the brake was applied lightly, 
the machine was switched off, and a reading was taken. A speed of 
6 rpm was then selected and a reading was recorded after 1 minute. 
Rotation was repeated at this speed until two identical readings 
were obtained. The plate and cone were washed with tap water, rinsed 
with distilled water, and the procedure repeated for each sample.
At 23 secs  ^ (6 rpm) the readings obtained were centipoise units of 
viscosity. At 230 secs  ^ (60 rpm) the readings were divided by 10 
to give actual units of viscosity. These units were of "measured" 
viscosity; that is, uncorrected for haematocrit.
2. Plasma Fibrinogen 
MATERIALS
Thorp Micro-nephelometer (Mark III) (Scientific Furnishings Ltd; 
kindly lent by ICl)
Polystyrene Latex Reference - 100 light-scattering units.
Buffered Saline, pH 6.3s
Two gm 2(n-morpholino) ethane-
sulphonic acid (MES) were dissolved in 1 litre 0.9^ NaCl 
The pH was adjusted to 6.3 using normal NaOH solution 
PROCEDURE (Stone et al,197l)
Plasma was separated from 2.5 ml blood containing EDTA as anti­
coagulant, which gives values for fibrinogen equal to those determined 
on native plasma. Fibrinogen was measured within 1 hour of the
collection of blood by nephelometry, a sensitive method for determining 
the light-scattering intensity (and hence concentration) of small 
particles in suspension.
Replicate samples were prepared by diluting 0.1 ml plasma with 
3.9 ml MES buffered saline in 12.5 ml tubes. This dilution of 1:40 
was suitable for normal levels of fibrinogen (200-400 mg/dl). For 
higher concentrations the estimation was repeated using a 1:100 
dilution* The nephelometer was calibrated using the polystyrene latex 
reference. Initial readings of the light-scattering intensity (LSI) 
of each sample were recorded to give blank values. The tubes were 
incubated at 56°C for 20 minutes to precipitate the fibrinogen, and 
cooled to room temperature. The tubes were wiped dry and a second 
LSI reading was obtained.
Fibrinogen concentration was calculated by the following equation:
Fibrinogen conc. (mg/dl) =
(Heated LSI - Blank LSI) x (a-— — ) x 0.054a
where a = volume plasma 
b = volume buffer 
The normal range of fibrinogen by this method is 200-400 mg/dl.
3. Haematocrit (Packed Cell Volume)
Blood (2.5 ml) collected at the same time as samples withdrawn 
for viscosity and fibrinogen estimations was anticoagulated with 
EDTA. The packed cell volumes were determined in the haematology 
laboratory, King's College Hospital.
4. Analysis of Results
Comparisons of measured viscosity, fibrinogen and haematocrit 
between controls and patients with IHD, or those with dysrhythmias, 
were made by Student's t test. Correlation coefficients were 
determined between haematocrit and the logarithms of measured
viscosity at each shear rate. The regression equations thus obtained 
were used to "correct" the viscosity readings to a standard haematocrit 
of 45 per cent. Correlation coefficients were then obtained between 
plasma fibrinogen and "corrected viscosity". Results obtained for 
measured viscosity and plasma fibrinogen after 6 weeks ascorbic acid 
treatment were compared with initial results by the paired t test. 
Results
The mean age of the 19 patients in whom viscosity and haematocrit 
were measured was 82 years (range 65-103 years).
1. Blood Viscosity
Means obtained for controls, patients with IHD and patients with 
dysrhythmias at both shear rates are shown in Table 13, The measured 
viscosity at 23 secs  ^was significantly greater in patients with IHl> 
than in controls (p < 0.02). No significant difference was observed 
between means for controls and patients with dysrhythmias, nor between 
patients with IHD and those with dysrhythmias.
At 230 secs  ^differences between means for the three groups were 
not significant.
TABLE 13 Blood Viscosity and Haematocrit in Aged Patients
Group 1 
n = 6
Group 2 
n = 7
Group 3 
n = 6
MEAN VISCOSITIES 
(centipoises) (+^  SE)
Shear rate 23 sec  ^
(measured)
7.08 (.55) 9.46 (.61) 8.29 (.34)
Shear rate 23 sec 1 
(corrected)
9.53 (.78) 10.70 (.52) 9.61 (.54)
Shear rate 230 sec  ^
(measured)
4.97 (.35) 5.70 (.26) 5.26 (.18)
Shear rate 230 sec  ^
(corrected)
MEAN HAEMATOCRIT °/o 
(+ SE)
35.3 (2.3) 40.8 (l.l) 40.8 (2.1)
6.13 (.33) 6.25 (.21) 5.80 (.28)
2. Haematocrit (Packed Cell Volume)
Mean (+ SE) haematocrit values for the three groups are shown in 
Table 13. The mean for patients with IHD was significantly greater 
than that for controls (p <* 0.05). Although the mean for patients 
with dysrhythmias was the same as that for patients with IHD, it did 
not differ significantly from the mean for controls owing to the higher 
variance of observations from the mean. All but one of the haematocrit 
values were below 45 per cent.
3. Relation of haematocrit to viscosity
Haematocrit values in the 19 patients were strongly correlated 
with the logarithm of viscosity measured at 23 secs  ^ (p <  0.001) 
and the logarithm of viscosity measured at 230 secs  ^ (p <  O.OOl).
A regression equation was obtained for each shear rate (Figures 18 
and 19) and used to correct all viscosity values to a standard 
haematocrit of 45 per cent. The mean "corrected" viscosities for each 
group are shown with the measured viscosities in Table 13.
4. Blood Viscosity - "corrected"
No significant differences were observed between the means for 
controls and patients with IHD, or those with dysrhythmias, at either 
shear rate.
5. Plasma Fibrinogen
This was measured in 48 patients, mean age 83 years (range 65- 
103 years). Mean fibrinogen values for controls, patients with IHD 
and patients with dysrhythmias are shown in Table 14. No significant 
differences were observed between the means. All but nine of the 48 
patients had fibrinogen levels within the normal range.
6. Relation of Fibrinogen to Viscosity
In the 19 patients for whom blood viscosity was determined, 
plasma fibrinogen was not significantly correlated with the measured
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viscosity at either shear rate, nor with the ’’corrected” viscosity 
at either shear rate.
TABLE 14 Plasma Fibrinogen Levels in Aged Patients Before and 
After Ascorbic Acid Treatment
Mean (+ SE) Plasma Fibrinogen mg/dl 
Initial Final
Group 1 (control) n = 20 340 23 302 _+ 20
Group 2 (IHD) n = 13 294 + 27 283 + 14
Group 3 (dysrhythmia) n = 15 310 + 20 305 + 19
Effects of Ascorbic Acid Treatment
1. Measured Viscosity
No significant changes were observed in the means for all 19 
patients at either shear rate, nor in the means obtained for each 
clinical group, before and after treatment (Table 15).
TABLE 15 Measured Viscosity in Aged Patients Before and After 
Ascorbic Acid
Mean Viscosity (centipoises)
23
-1secs to o -1secs
Initial Final Initial Final
All patients n = 19 8.58 8.40 5.44 5.03
Group 1 n = 6 7.08 7.90 4.97 4.47
Group 2 n = 7 9.46 9.41 5.70 5.50
Group 3 n = 6 8.29 7.90 5.26 4.99
2, Haematocrit
Haematocrit values remained unchanged after six weeks ascorbic 
acid administration.
3. Fibrinogen
Although mean fibrinogen concentrations were not significantly- 
changed in the 13 patients who had IHD (Group 2), nor in the 15 
patients who had dysrhythmia-ischaemia (Group 3)j the mean for 20 
control patients was significantly reduced after six weeks ascorbic 
acid treatment (p < O.Ol) (Table 14). Fibrinogen concentrations were 
reduced in each of the nine patients with above normal initial levels. 
However, no correlation was observed between initial blood ascorbic 
acid levels and plasma levels of fibrinogen.
Discussion
The aged patients with THD had a significantly higher blood 
viscosity than controls, at a low shear rate (23 secs ^). The haem­
atocrit was also significantly greater in patients with IHD and when 
the viscosity results were "corrected” to a standard haematocrit of 
45 per cent, there were no significant differences between mean 
viscosities for the three groups of patients at either shear rate.
This suggests that the higher haematocrit in patients with IMP was 
responsible for the greater blood viscosity in this group and, indeed, 
haematocrit was strongly correlated with viscosity at both shear rates. 
Similar findings have been reported in patients with intermittent 
claudication (Hamer et al,1973) and in younger patients with angina 
(Nicolaides et al,1977) in whom viscosity was higher than that in 
controls at four shear rates, but was not significantly different when 
corrected to a haematocrit of 45 per cent. It may be worth noting 
that all but one of the 19 aged patients had a haematocrit value below 
45 per cent. Hawkins and colleagues (1954) and Elwood (1971) found a 
decrease in haematocrit with age. In younger patients with arterial 
disease the increased haemoglobin concentration which is commonly found 
is due to a decreased plasma volume in the presence of a normal red cell
mass (Burge et al,1975) and the mortality ra,te in these patients with
in
"pseudopolycythaemia" is greater thaiy those with normal haemoglobin 
levels. An investigation of 19,000 women (Elwood et al,1974) showed 
a distinct increase in mortality in subjects with haematocrit above 
46° jo , with an increased proportion of deaths due to cardiovascular 
disease. In anaemic women the proportion of deaths due to cardio­
vascular diseases was decreased. Furthermore, there is an increased 
incidence of stroke in subjects with raised haemoglobin and haemato­
crit levels (Ostfeld,1975) and cerebral blood flow was reduced in 
patients with a haematocrit above 46 per cent (Thomas et al,1977).
The aged patients with dysrhythmia-ischaemia had mean blood 
viscosity values midway between the means for controls and the patients 
with IHD, but were not significantly different from the control values. 
Thus, in this small group of patients, blood viscosity (and its effects 
on blood flow) was not associated with defects of the cardiac conduction 
tissue in which ageing changes may play the most important role.
Although plasma fibrinogen levels were shown to be raised in 
patients with peripheral ischaemic disease and with angina, and 
fibrinogen was related to blood viscosity in these patients (Dormandy 
et al, 1-974; Stormer et al,1974; Nicolaides et al,1977) plasma 
fibrinogen levels were not significantly different in aged patients 
with IHD, nor in aged patients with dysrhythmias, when compared with 
levels for controls. Only nine of the 48 patients had fibrinogen levels 
above the upper limit of normal (400 mg/dl). Moreover, fibrinogen 
levels were not correlated with viscosity at either shear rate in the 
nineteen patients in whom both parameters were measured, even when 
viscosity was corrected to eliminate the effect of haematocrit.
Fibrinogen concentrations are affected in a number of disease conditions, 
including osteoarthritis and acute infections, which may be relevant 
in these aged patients, although the majority had normal levels.
Fibrinogen metabolism may also be affected by ageing. Plasma proteins 
are reduced in cnncentration with age (Nocker and Bemm,1955) but only 
slight changes in protein synthetic capacity have been demonstrated 
in aged liver tissue (Hall,1973)*
Although ascorbic acid treatment had no effect upon viscosity 
or haematocrit, nor upon mean fibrinogen levels in patients with IHD 
or dysrhythmias, six weeks administration of ascorbic acid was 
associated with a significant reduction in the mean fibrinogen 
concentration in 20 aged patients who acted as controls. Moreover, 
fibrinogen levels were reduced in each of the nine patients whose 
initial levels had been raised. Salmon and May (1952) noted that in 
scorbutic monkeys the bone marrow coagulated very rapidly and the 
plasma fibrinogen was found to be elevated. Further studies revealed 
that ascorbic acid deficiency produced a marked rise in plasma 
fibrinogen independently of total plasma protein levels, which tended 
to decline. After treatment with ascorbic acid the fibrinogen levels 
returned to normal. Similar findings were obtained in an early study 
of ascorbic acid-deficient and scorbutic guinea pigs (Sullivan et al,
1944).
Fibrinogen synthesis may be stimulated by free fatty acid 
mobilisation (Pickart and Thaler,1976) (Figure 16) and a striking 
rise in circulating free fatty acids was observed in ascorbic acid- 
deficient monkeys (Banerjee and Bandyopadhay,1965)* The highest 
concentrations of ascorbic acid in body tissues are in the adrenal 
glands, where ascorbic acid acts as a cofactor in the biosynthesis 
of norepinephrine from dopamine (Friedman and Kaufman, 19,65)* A,scorbic 
acid and adrenocorticotrophic hormone (ACTH) may have opposing roles 
in free fatty acid utilisation in sterdidogenesis (Kitabchi,1967) 
mediated by the adrenal hydroxylase system. ACTH increases the free
fatty acid content of adrenal preparations in vitro and increases 
plasma levels of free fatty acids and fibrinogen (Pickart and Thaler,
1976). The raised fibrinogen concentration found in ascorbic acid 
deficiency may be mediated by an increased mobilisation of free 
fatty acids. However, much further work is required in investigating 
both the synthesis of fibrinogen and the role of ascorbic acid in the 
adrenal medulla and cortex, in order to clarify the effects of ascorbic 
acid on fibrinogen metabolism. In the aged patients included in the 
present study there was no correlation between initial blood levels 
of ascorbic acid and plasma fibrinogen concentrations.
In summary, a raised blood viscosity at a low shear rate was 
associated with clinical IHD in aged patients but not with 
dysrhythmia-ischaexnia. Viscosity was influenced by the haematocrit, 
but not by plasma fibrinogen levels. By reducing coronary blood flow 
an increased blood viscosity may be of aetiological importance in 
myocardial ischaemia in aged patients, in whom compensatory mechanisms 
are affected by ageing changes in the heart and blood vessels.
CHAPTER 7
GENERAL DISCUSSION
This work has investigated ischaemic heart disease in old people 
by seeking to integrate four points of view.
Blood flow to the myocardium can be reduced by coronary arterial 
obstruction, coronary hypoperfusion during dysrhythmias, and by the 
rheological effects of increased blood viscosity. In investigating _ 
the importance of lipid levels to both the pathological findings of 
coronary arterial obstruction and the clinical diagnosis of IHD, and 
in studying the metabolic effects of ascorbic acid on lipoproteins 
and rheological factors, this work has sought to show that even in 
old age, IHD is associated with metabolic factors that might be controlled 
by earlier treatment.
IHD in the aged patient can produce particularly severe impair­
ment of physical and mental capacity and is a growing community health 
problem as the number of aged persons in the population increases. At 
any age there are many factors associated with the development of IHD 
but in the old person the picture is further complicated by ageing 
changes in the heart and blood vessels. Indeed, in the past, IHD has 
been too readily dismissed as an inevitable consequence of ageing.
In younger patients who have IHD a common finding is abnormal lipid 
metabolism, and raised serum levels of cholesterol and triglyceride 
are risk factors for the future development of the disease. However, 
hyperlipidaemia was almost absent in men over 70 years who had survived 
myocardial infarction (Goldstein et al,1973) and hyperlipidaemia has 
little predictive value in men over 60 years of age (Carlson and 
Bottiger,1972). Indeed, the present pathological investigation showed 
that in cases of sudden death, cholesterol levels measured at autopsy 
were negatively correlated with age and clinically, the majority of 
aged patients had lipid levels which would be considered normal or low 
in younger people. Despite these findings, cholesterol levels at
autopsy in cases over 60 years were significantly greater in men with 
thrombotic occlusion of the coronary arteries than in those without, 
and aged men with clinical evidence of JHD had significantly higher 
levels of serum cholesterol than male controls. Clearly, the criteria 
used for defining hyperlipidaemia in younger people cannot be applied 
in the elderly.
The lower lipid levels found in advanced age are possibly due in 
part to the earlier deaths of patients with severe hyperlipidaemias 
(for example, familial hypercholesterolaemia) but these patients 
represent a relatively small section of the community. It is likely 
that ageing changes in hormonal and enzyme systems make the biggest 
contribution to the relative absence of hyperlipidaemia in the elderly. 
The aged patients with IHD, who had comparatively raised lipid levels, 
may represent survivors of earlier hyperlipidaemias, in whom long­
standing coronary arterial obstruction is aggravated by ageing 
impairment of myocardial contraction (Kohn and Rollerson,1959) and 
loss of elastic tissue. Nevertheless, the findings at autopsy in men 
of all ages suggest an association of cholesterol levels with the 
active process of thrombus formation. Although these results must be 
treated with caution since it is not known to what extent cholesterol 
levels measured at autopsy reflect serum levels measured clinically, 
they may have important implications in the controversy of athero- 
genesis and in the question whether thrombosis is a cause or a result 
of myocardial infarction.
In women, cholesterol levels were not associated with coronary 
vessel occlusion at autopsy, nor were they significantly raised in 
aged women with clinical IHD. However, triglyceride levels were raised 
in these women and it was found that, irrespective of diagnosis, total 
and VLDL-triglyceride levels in aged women were negatively correlated
with concentrations of HDL-cholesterol. Similar metabolic inter­
relations have been found in younger people (Carlson,19735 Schaeffer 
et al,1978). HDL-cholesterol levels were greater in women than in 
aged men and similar findings in younger age groups (Carlson and 
Ericsson,1975) suggest that higher levels of HDL-cholesterol may protect 
women against IHD in earlier life, since low HDL-cholesterol is strongly 
associated with the future development of the disease (Gordon et al,
1977). Indeed, in both aged men and women with IHD, HDL-cholesterol 
as a percentage of total circulating cholesterol was significantly 
lower than in controls.
The pathology results showed that in cases of sudden death over 
60 years of age, the incidence of total occlusion was only half that 
found in younger cases. It is possible that in the older cases without 
evidence of occlusive thrombus, ageing changes in the myocardium, aorta 
and specialised conducting tissue reduced the efficiency of the 
compensatory mechanisms which maintain coronary blood flow during 
stress. The clinical and electrocardiographic findings showed that 
myocardial ischaemia in aged patients can be precipitated by supra­
ventricular dysrhythmia. It is difficult to determine which pathological 
changes can be correctly attributed to ageing but in the majority of 
our patients dysrhythmia-ischaemia was not associated with abnormalities 
of lipid metabolism. However, the raised serum cholesterol levels 
found in some patients with dysrhythmias suggest that coronary arterial 
disease had contributed to myocardial ischaemia in these cases.
Rheological factors, as well as lipid abnormalities, were associated 
with clinical IHD in aged men and women. The raised blood viscosities 
found in patients with IHD were related to higher haematocrit values 
but not to fibrinogen levels. Other factors which influence blood 
viscosity, such as erythrocyte flexibility, were not examined. Patients 
with dysrhythmia-ischaemia did not have significantly raised blood
viscosity values which further suggests that myocardial ischaemia in 
many of these patients is associated with impaired function as a 
result of ageing changes in the cardiac conducting tissue, rather than 
with the effects of viscosity or vessel narrowing on coronary blood 
flow.
If the metabolic disorders found in aged patients with I HI) have 
contributed to the aetiology of the disease, treatment of these 
disorders would have obvious usefulness in earlier protection against 
IHD. In younger people the reduction of serum cholesterol by modifying 
dietary fats was not shown to have any clinical benefit (Medical Research 
Council,1965) but was reported to reduce mortality from iHl) in men in 
Finland (Meittenen et al,1972). At present it is not known whether HDL 
has a direct association with coronary arterial disease and the 
benefits of therapy designed to raise plasma levels of HDL have not 
yet been demonstrated. Reports on the effects of ascorbic acid treatment 
on serum cholesterol levels in men have been equivocal (Ginter et al,
I97O5 Peterson et al,1975) and may depend on initial ascorbic acid 
status as well as on the presence of specific lipid disorders. Blood 
ascorbic acid levels in our aged patients were low, and in men were 
significantly correlated with levels of HDL-cholesterol, in agreement 
with the findings of Bates and colleagues (1977). Furthermore, in all 
the men, and in women with IHD, six weeks treatment with daily gram 
doses of ascorbic acid resulted in a significant increase of HDL- 
cholesterol. Total cholesterol was also reduced by ascorbic acid 
in the aged men who had TFTD and in one woman patient who had overt 
hypercholesterolaemia. The mechanism of ascorbic acid in lipoprotein 
metabolism is not clear. The vitamin had no direct effect on LCAT 
activity (expressed as the rate of cholesterol esterification) but 
may be a co-factor in lipoprotein lipase activity (Sokoloff et al,1966) 
and the cholesterol-7a-hydroxylase system in bile acid synthesis
(Ginter,1973).
A further interesting finding in association with ascorbic acid 
treatment was a reduction in plasma fibrinogen in the nine aged 
patients with raised initial levels. Although there was no relation 
between blood viscosity and fibrinogen in these aged men and women, 
raised fibrinogen levels have been found in patients with peripheral 
vascular disease (Dormandy et al,1973) and in younger patients with 
angina (Nicolaides et al,1977). The effects of ascorbic acid in these 
aged patients imply that the vitamin may have a role in the earlier 
protection against IHD.
The daily degradation of ascorbic acid in the body pool of adult 
man was estimated to be 45 mg (Kallner et al,1977). The present 
recommended allowance in the United Kingdom of 30 mg per day is there­
fore too low, and chronic latent ascorbic acid deficiency is a 
potentially prevalent health risk. A recent estimate based on 
metabolic studies of ascorbic acid turnover and the amounts required 
to maintain body pool size suggests that the daily requirement of 
ascorbic acid in man is about 100 mg (Hornig,1978). There is no evidence 
to show that requirements are reduced in old age and since ascorbic 
acid has a physiological role in connective tissue maintenance, latent 
deficiency of the vitamin may accelerate degenerative changes in tissue 
structure and function.
Mortality from I HD in the United States has declined in the period 
1963-1975 in all age groups including the over 85s (Florey et al,1978) 
and this decline coincides with the reduced consumption of animal fats 
and tobacco. No such encouraging decline has occurred in England and 
Wales, and Passmore and colleagues (1979) in the "Prescription for a 
better British diet" have recommended a reduced intake of fat, sugar, 
meat and alcohol, and an increase in consumption of cereals, potatoes, 
other vegetables and fruit. Such a diet should increase the intake of 
ascorbic acid.
In conclusion, ascorbic acid appears to participate in a variety 
of enzyme and immune systems and much further work is required to 
elucidate these. The precise nature of its roles in lipoprotein and 
fibrinogen metabolism in man may be revealed only when the regulation 
of cholesterol levels and the synthesis of fibrinogen are themselves 
more fully understood. While this work has examined aspects of IHD 
in aged patients from four points of view, it has concentrated on 
pathological changes in the cardiovascular system itself. Future work 
may reveal the importance of ageing processes in other organs, such as 
the thyroid and adrenal glands, to cardiovascular function in old age. 
At present the ageing changes which occur in the specialised cardiac 
conduction tissue cannot be prevented but dysrhythmias do respond to 
specific therapy, while earlier long-term nutritional measures may 
aid in protecting against the disabling effects of coronary arterial 
disease in old age.
APPENDIX
Cholesterol Levels in Atrial Plasma and Coronary Vessel Status at 
Autopsy (Chapter 2)
Abbreviations: T = occlusive thrombus; S = stenosis; MI = myocardial
infarction; - = other (e.g.hypertension,cor pulmonale)
TABLE 2:16 Autopsy Details
se No. Sex Age PM Diagnosis CH0L
(mg/dl)
Heart we: 
(gm)
1 M 45 T 319 700
2 M 55 T 299 530
3 M 55 S 210 470
4 M 40 S 211 450
5 M 71 MI 320 530
6 M 70 T 228 430
7 M 53 T 364 450
8 P 78 S 199 420
9 F 74 S 197 500
10 M 34 MI 330 480
11 M 51 T 342 450
12 M 67 T 259 500
13 M 78 - 182 340
14 M 52 S 281 500
15 M 77 s 261 405
16 F 76 s 399 450
17 M 59 MI 388 600
18 M 78 S 182 600
19 F 62 T 121 325
20 F 81 - 174 485
21 M 55 S 264 540
22 M 68 - 255 670
23 F 42 T 298 280
24 F 64 - 348 750
25 F 82 - 271 320
26 F 56 T 240 350
27 F 61 S 285 500
28 M 74 S 241 430
29 M 65 S 229 520
30 M 61 S 240 470
TABLE 2:16 Autopsy Details contfd
Case No, Sex Age PM Diagnosis CHOL
(mg/dl)
Heart weight
( m )
31 M 56 T 358 430
32 M 48 T 317 410
33 M 60 T 263 530
34 F 52 T 337 400
35 M 59 T 286 570
36 F 79 S 226 440
37 M 64 T 265 500
38 M 68 S 208 510
39 M 59 T 225 420
40 M 76 S 298 700
41 F 83 T 205 345
42 M 56 MI 470 420
43 F 62 T 315 380
44 M 66 S 214 500
45 F 87 T 218 520
46 M 58 S 308 390
47 M 53 T 326 680
48 F 50 T 231 400
49 M 67 S 215 640
50 F 51 - 197 300
51 M 58 T 281 420
52 M 74 T 372 470
53 M 60 T 258 500
SERUM CHOLESTEROL AND TRIGLYCERIDE LEVELS IN AGED MEN WITH IHD 
(Chapter 3)
Summary of Clinical Details
Abbreviations used in Tables:
AE = atrial fibrillation
CCF = congestive cardiac failure
RBBB/LBBB = right/left bundle branch block 
CVA = cerebrovascular accident
SVT = supraventricular tachycardia
MI = myocardial infarction
HT = hypertension
Ca = carcinoma
CB = chronic bronchitis
OA,RA = osteo-/rheumatoid arthritis
-  fracture
WNL = ECG within normal limits
TABLE 3s17 Group 1 (controls) Clinical Details
Patient Age Clinical/ECG CHOL T.G.
(mg/dl) (mg/dl)
1 (FA) 72 Ca Lung, WNL 169 56
2 (d p ) 84 Parkinsonism, EBBB,CCF 146 76
3 (ws) 84 Falls, CB, WNL 138 73
4 (m m ) 76 ^  skull, WNL 179 70
5 (SA) 70 ^  neck L femur, WNL 152 106
6 (JP) 69 R CVA, confused, WNL 158 50
7 (ws) 82 Parkinsonism, CB, falls 170 74
8 (EC) 75 RA, incipient respiratory 
failure
177 53
9 (g g ) 84 CB, rectal prolapse, WNL 162 72
10 (PL) 85 CCF, WNL 129 71
11 (g l ) 90 Ca prostate, R CVA, WNL 179 46
12 (TH) 74 CB, RBBB, WNL 132 53
13 (®) 82 L CVA, WNL 158 98
14 (h l ) 71 R CVA, HT, WNL 184 94
15 (AF) 75 neck femur, L CVA, 
HT, CB, WNL
201 102
TABLE 3:18 Group 2 (.TUB) Clinical Details
Patient Age Clinical/ECG CHOL T.G.
(mg/dl) (mg/dl)
16 (GF) 80 MI, atheroma confirmed 
by PM
139 159
17 (mo*d) 70 MI, 3 x CVA, CCF 207 93
18 (ES) 79 MI, EBBB 205 215
19 (GM) 67 MI, CVA 178 109
20 (EH) 89 MI, bilateral CVA, EBBB, 
transient AF
221 79
21 (SF) 70 MI, R CVA, EBBB,confusion 233 77
22 (WE) 92 MI, CCF, bronchopneumonia 159 67
23 (AW) 76 L CVA, HT, CCF, ischaemic 
ECG
220 88
24 (HH) 85 MI, falls, confusion 236 100
25 (EL) 87 MI, CCF, Parkinsonism, 
RBBB
236 116
26 (AP) 72 CCF, ischaemic ECG 185 176
27 (LJ) 84 R CVA, falls, ischaemic 
ECG
233 98
TABLE 3:19 Group 3 (dysrhythmia-ischaemia) Clinical Details
Patient Age Clinical/ECG CH0L 
(mg/ dl)
T.G,
(mg/<
28 (HW) 80 Falls, CB, cor pulmonale, 
AF
201 59
29 (JG) 71 Syncope palpitans, LBBB, 
SVT
176 64
0 1 87 RBBB, LBBB, ventricular 
conduction delay
185 81
31 (ES) 76 L CVA, falls, # femur,AF 173 64
32 (SK) 86 Falls, heart block, 
ventricular ectopic 
beats
250 72
33 (RE) 88 Brain failure, R + LBBB, 
SVT
196 59
34 (RS) 81 Stokes-Adams attacks, 
brain Jailure
203 68
35 .(JW) 81 Brisk carotid sinus reflex 226 97
36 (FB) 72 #  femur, paroxysmal AF 157 97
37 (HC) 70 L CVA, paroxysmal SVT 156 59
38 (WD) 80 Falls, Parkinsonism,
Stokes-Adams attacks, 
RBBB
152 43
39 (TS) 87 Falls, CB, cor pulmonale, 
AF
180 91
40 (L0) 70 R CVA, AF 131 96
41 (WH) 90 Falls, AF 184 148
42 (AT) 72 Mild L CVA, CCF, AF 197 91
Effects of Ascorbic Acid on Lipoproteins in Aged Men and Women 
(Chapter 4)
Clinical/Ascorbic Acid StatusTABLE 4:20 Group 1 
Patient Age Sex
43 (HJ) 74 F
44 (ES) 94 F
45 (m t ) 93 F
46 (EH) 81 F
47 (EC) 94 F
48 (m b ) 95 F
49 (BB) 75 M
50 (m e ) 82 M
51 (wr) 82 M
52 (ws) 73 M
53 (SH) 74 M
54 (JM) 70 M
55 (CB) 75 F
56 (e t ) 79 M
Clinical/ECG
L CVA, epilepsy, WNL
Paget*s, ^tibia, WNL
Diverticular disease, 
WNL
Paget*s, /^hip, WNL
Falls, OA, WNL
OA hip, WNL
Falls, depression, 
blind
Leg ulcers, CCF, 
partial RBBB
Ca prostate, WNL
Paget*s skull and hip, 
WNL
CVA, WNL
CVA, WNL
R CVA, Haemangioma- 
tosis, WNL
R CVA, Parkinsonism, 
WNL
AA
WBC
I II 
24 41
AA
PLASMA
I 11 
0.46 0.90
34 39 0.69 0.84
27 42 0.34 2.01
17 33 0.02 1.56
14 27 0.10 0.33
22 33 0.69 1.33
18 28 Os 08 0.69
21 32 0.12 0.97
26 31 0.31 0.42
23 29 0.18 1.21
27 43 0.24 0.86
11 29 0.03 0.88
17 29 0.26 0.95
28 36 0.31 0.69
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TABLE 4:22 Group 2 Clinical/Ascorbic Acid Status
Patient Age Sex Clinical/ECG AA
WBC
AA
PLASMA
57 (EM) 97 F Recurrent CYAs, OA 
knees, MI
I
17
II
34
I
0.21
II
0.34
58 (AG) 93 F Repeated falls, MI 26 38 0.43 1.07
59 (CA) 79 F R CVA, MI, HT 23 31 0.12 1.26
60 (hc) 83 M L CVA, chest pain 
ischaemic ECG
19 31 — —
61 (LC) 76 F MI, L CVA, HT 20 26 0.33 0.65
62 (JC) 71 M femur, old MI 15 26 0.04 0.93
63 (BE) 87 F MI, confused 19 29 0.19 0.42
64 (FA) 77 M Angina pectoris, CB, 
R CVA, MI
27 32 0.42 0.51
65 (EH) 86 M R CVA, MI, RBBB 21 35 - -
66 (MD) 84 M Peripheral vascular 
disease, MI, RBBB, 
AF
* 28 41
67 (CC) 65 M MI, epilepsy 19 26 - -
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TABLE 4:24 Group 3 Clinical/Ascorbic Acid Status
Patient Age Sex Clinical/ECG AA AA
WBC PLASMA
I II I II
68 (EG) 83 F Blackouts, falls, 
syncope palpitans
22 30 0.09 0.42
69 (EC) 90 F RA, OA, RBBB, atrial 
premature beats
22 34 0.34 0.78
70 (GW) 77 F R CVA, Stokes-Adams 
attacks
23 39 0.16 1.49
71 (LC) 79 F CCF, Stokes-Adams 
attacks
15 29 0.14 0.74
72 (RO) 94 F L CVA, AF 31 38 0.29 0.76
73 (ET) 85 M R CVA, Atrial flutter 23 24 0.12 0.31
74 (AK) 91 F R CVA, bradycardia 31 54 0.28 2.04
75 (MS) 82 F L CVA, OA, syncope 
palpitans
29 44 0.10 1.11
76 (WW) 77 M CVA, Parkinsonism, 
bradycardia
26 28 0.15 0.29
77 (SH) 83 M 59s femur, AF 33 36 - -
78 (CR) 87 M Falls, atrial premature 
beats
34 32 — —
79 (SC) 69 M Complete heart block, 21 40 - -
pacemaker fitted
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Cholesterol Esterifying Activity (Chapter 5)
TABLE 5*26 Eate of Esterification: Effects of AA
Patient Age Sex Group Eate jig/ml/hr HDL-chol mg/dl
z u X F
80 (t t ) 73 M 2 0 43 51
81 (a m ) 79 M 1 1 2 22 20
82 (b w ) 88 E 2 1 63 62
83 (MS) 88 F 1 13 7 58 60
84 (AS) 103 F 5 5 57 53
85 (l s ) 84 F 1 0 4 49 55
60 (h c ) 83 M 2 11 17 27 39
65 (e h ) 86 M 2 5 1 25 38
66 (m d ) 84 M 2 2 7 29 41
67 (cc) 65 M 2 4 6 24 31
86 (e d) 74 F 2 6 10 51 54
87 (l c ) 85 F 2 15 14 49 56
88 (lii) 88 F 2 12 4 48 49
77 (SH) 83 M 3 4 0 49 55
78 (c e) 87 M 3 9 17 42 48
79 (sc) 69 M 3 10 0 37 35
89 (EM) 73 F 3 23 16 63 59
90 (a n ) 83 F 3 0 27 42 51
91 (b a ) 91 F 3 1 11 49 47
PCV, Blood Viscosity and Plasma Fibrinogen in Aged Patients 
(Chapter 6)
TABLE 6:27 Measured and "Corrected” Viscosities
Viscosity (centipoises)
Patient Group PCV °/o
80 (t t) 1 32.5
81 (a m ) 1 28.5
82 (b w ) 1 30.4
83 (MS) 1 43.4
,84 (AS) 1 38.6
85 (LS) 1 38.1
60 (h c ) 2 44.7
65 (e h ) 2 40.7
66 (m d ) 2 41.4
67 (CC) 2 38.8
86 (ED) 2 42.1
87 (l c ) 2 42.5
88 (l h ) 2 35.2
77 (SH) 3 43.2
78 (c r) 3 33.6
79 (sc) 3 40.0
89 (EM) 3 42.7
90 (a n ) 3 48.4
91 (b a ) 3 36.9
Equations used in correction to 
Shear rate 23 sec”'*':
Log10 v45 = Log10 
Shear rate 230 sec“ .
Log10 V45 = L°g10
23 sec”x to 0 sec
M "C" M "C"
6.5 9.53 4.5 5.93
5.0 8.29 3.7 5.33
8.5 13.29 5.5 7.60
8.5 8.93 6.2 6.42
7.5 9.12 5.0 5.76
6.5 8.03 4.9 5.71
10.5 10.59 6.6 6.75
10.5 11.97 6.0 6.60
9.75 10.89 6.1 6.6l
6.5 7.86 4.6 5.28
10.0 10.93 5.3 5.65
11.0 11.88 6.1 6.45
8.0 10.80 5.2 6.46
9.0 9.51 5.5 5.72
7.5 11.63 5.2 6.69
8.75 10.20 5.6 6.25
9.0 9.66 5.7 6.00
8.5 7.66 5.1 4.73
7.0 8.97 4.5 5.38
PCV h:5°/o
V + 0.0133 (45-PCV)
V + 0.0096 (45-PCV)
TABLE 6:28 Fibrinogen (mg/dl):Effects of AA
Group 1 Group 2 Group 3
Patient I II Patient I II Patient I II
43 262 153 57 223 268 68 217 169
44 264 241 58 211 204 69 383 356
45 233 185 59 287 310 70 320 295
46 376 367 60 207 246 71 241 226
47 188 301 61 224 264 72 284 247
48 400 346 62 195 307 73 277 321
49 282 194 88 227 238 74 374 413
50 574 429 64 212 251 75 315 254
51 274 211 65 346 301 76 255 219
52 388 370 66 568 411 77 218 336
53 289 243 67 370 287 78 408 399
54 285 237 86 444 325 79 489 310
55 282 194 87 3 08 272 89 352 402
56 279 303 90 224 316
80 516 453 91 292 306
81 275 278
82 506 489
83 349 299
84 382 355
85 257 261
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